<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="89ea44f6-7341-4c14-9098-e7a3da6ee7bb"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use PAXLOVID safely and effectively. See full prescribing information for PAXLOVID.<br/>
      <br/>PAXLOVID<sup>TM</sup> (nirmatrelvir tablets; ritonavir tablets), co-packaged for oral use <br/>Initial U.S. Approval: 2023</title>
   <effectiveTime value="20250415"/>
   <setId root="8a99d6d6-fd9e-45bb-b1bf-48c7f761232a"/>
   <versionNumber value="8"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="134489525" root="1.3.6.1.4.1.519.1"/>
            <name>Pfizer Laboratories Div Pfizer Inc</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="113480771" root="1.3.6.1.4.1.519.1"/>
                  <name>Pfizer Inc</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="985052076" root="1.3.6.1.4.1.519.1"/>
                        <name>Pfizer Ireland Pharmaceuticals Unlimited Company</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5045" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5321" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5317" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-0521" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5045" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5321" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5317" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-0521" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="341970073" root="1.3.6.1.4.1.519.1"/>
                        <name>Pfizer Manufacturing Deutschland GmbH</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5045" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5321" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5317" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5045" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5321" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5317" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5045" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5321" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5317" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5045" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5321" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5317" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="986019327" root="1.3.6.1.4.1.519.1"/>
                        <name>Pfizer Ireland Pharmaceuticals Unlimited Company</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5045" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5321" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5317" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-0521" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5045" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5321" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5317" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-0521" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5045" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5321" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5317" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-0521" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5045" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5321" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5317" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-0521" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="458521908" root="1.3.6.1.4.1.519.1"/>
                        <name>Pfizer Italia S.r.l.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5045" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5321" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5317" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5045" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5321" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5317" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5045" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5321" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5317" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5045" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5321" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5317" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="943955690" root="1.3.6.1.4.1.519.1"/>
                        <name>Pfizer Inc</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5045" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5321" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0069-5317" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="e2cf1009-1e40-48ed-a654-b422e98bc9b4"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250212"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0069-5045" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Paxlovid</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>nirmatrelvir and ritonavir</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0069-5045-06" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0069-5045-30" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20230525"/>
                                          <high value="20230525"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="1" value="20"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0069-2085" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Nirmatrelvir</name>
                              <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>nirmatrelvir</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="150"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="7R9A5P7H32" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>NIRMATRELVIR</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="7R9A5P7H32" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>NIRMATRELVIR</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SILICON DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CROSCARMELLOSE SODIUM</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTOSE MONOHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MICROCRYSTALLINE CELLULOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM STEARYL FUMARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="0HO1H52958" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE 2910 (10000 MPA.S)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FERRIC OXIDE RED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TITANIUM DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="2"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0069-2085-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA217188" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20230525"/>
                                    <high value="20230525"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PINK" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="18" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">PFE;3CL</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator unit="1" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0069-1345" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Ritonavir</name>
                              <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>ritonavir</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="100"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="O3J8G9O825" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RITONAVIR</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="O3J8G9O825" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>RITONAVIR</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="L11K75P92J" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ANHYDROUS DIBASIC CALCIUM PHOSPHATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SILICON DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="D9C330MD8B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>COPOVIDONE K25-31</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM STEARYL FUMARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6W9PS8B71J" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SORBITAN MONOLAURATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 400</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 3350</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TALC</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TITANIUM DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0069-1345-11" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA217188" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20230525"/>
                                    <high value="20230525"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                                    <originalText>white to off-white</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="18" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                                    <originalText>Capsule</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">H;R9</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217188" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20230525"/>
                              <high value="20230525"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0069-5321" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Paxlovid</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>nirmatrelvir and ritonavir</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0069-5321-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0069-5321-30" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20231018"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="1" value="20"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0069-2085" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Nirmatrelvir</name>
                              <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>nirmatrelvir</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="150"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="7R9A5P7H32" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>NIRMATRELVIR</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="7R9A5P7H32" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>NIRMATRELVIR</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SILICON DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CROSCARMELLOSE SODIUM</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTOSE MONOHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MICROCRYSTALLINE CELLULOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM STEARYL FUMARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="0HO1H52958" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE 2910 (10000 MPA.S)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FERRIC OXIDE RED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TITANIUM DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="2"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0069-2085-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA217188" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20231018"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PINK" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="18" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">PFE;3CL</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator unit="1" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0069-1735" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Ritonavir</name>
                              <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>ritonavir</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="100"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="O3J8G9O825" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RITONAVIR</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="O3J8G9O825" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>RITONAVIR</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="L11K75P92J" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ANHYDROUS DIBASIC CALCIUM PHOSPHATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SILICON DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="D9C330MD8B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>COPOVIDONE K25-31</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM STEARYL FUMARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6W9PS8B71J" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SORBITAN MONOLAURATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE, UNSPECIFIED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 3350</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 400</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TALC</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TITANIUM DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0069-1735-11" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA217188" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20231018"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="17" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                                    <originalText>ovaloid</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">NK</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217188" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231018"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0069-5317" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Paxlovid</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>nirmatrelvir and ritonavir</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0069-5317-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0069-5317-20" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20231018"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="1" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0069-2085" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Nirmatrelvir</name>
                              <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>nirmatrelvir</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="150"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="7R9A5P7H32" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>NIRMATRELVIR</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="7R9A5P7H32" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>NIRMATRELVIR</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SILICON DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CROSCARMELLOSE SODIUM</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTOSE MONOHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MICROCRYSTALLINE CELLULOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM STEARYL FUMARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="0HO1H52958" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE 2910 (10000 MPA.S)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FERRIC OXIDE RED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TITANIUM DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0069-2085-11" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA217188" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20231018"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PINK" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="18" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">PFE;3CL</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator unit="1" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0069-1735" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Ritonavir</name>
                              <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>ritonavir</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="100"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="O3J8G9O825" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RITONAVIR</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="O3J8G9O825" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>RITONAVIR</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="L11K75P92J" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ANHYDROUS DIBASIC CALCIUM PHOSPHATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SILICON DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="D9C330MD8B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>COPOVIDONE K25-31</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM STEARYL FUMARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6W9PS8B71J" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SORBITAN MONOLAURATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE, UNSPECIFIED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 3350</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 400</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TALC</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TITANIUM DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0069-1735-11" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA217188" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20231018"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="17" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                                    <originalText>ovaloid</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">NK</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217188" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231018"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0069-0521" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Paxlovid</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>nirmatrelvir and ritonavir</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0069-0521-11" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250415"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="1" value="6"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0069-2085" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Nirmatrelvir</name>
                              <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>nirmatrelvir</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="150"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="7R9A5P7H32" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>NIRMATRELVIR</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="7R9A5P7H32" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>NIRMATRELVIR</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SILICON DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CROSCARMELLOSE SODIUM</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTOSE MONOHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MICROCRYSTALLINE CELLULOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM STEARYL FUMARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="0HO1H52958" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE 2910 (10000 MPA.S)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FERRIC OXIDE RED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TITANIUM DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="6"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0069-2085-06" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA217188" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250415"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PINK" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="18" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">PFE;3CL</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator unit="1" value="5"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0069-1735" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Ritonavir</name>
                              <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>ritonavir</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="100"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="O3J8G9O825" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>RITONAVIR</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="O3J8G9O825" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>RITONAVIR</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="L11K75P92J" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ANHYDROUS DIBASIC CALCIUM PHOSPHATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SILICON DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="D9C330MD8B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>COPOVIDONE K25-31</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM STEARYL FUMARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6W9PS8B71J" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SORBITAN MONOLAURATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE, UNSPECIFIED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 3350</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 400</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TALC</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TITANIUM DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="5"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0069-1735-05" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA217188" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250415"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="17" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                                    <originalText>ovaloid</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">NK</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217188" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250415"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_912D8D32-79FA-4ABB-B94D-F4B6C75F06F9">
               <id root="812b518c-8768-4796-8032-5b07fc68c170"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <table styleCode="Noautorules" width="100%">
                           <col width="91%"/>
                           <col width="9%"/>
                           <tbody>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Dosage and Administration, Important Dosage and Administration Information (<linkHtml href="#S2.1">2.1</linkHtml>)</paragraph>
                                 </td>
                                 <td align="right" valign="top">
                                    <paragraph>01/2025</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Dosage and Administration, Dosage in Patients with Renal Impairment (<linkHtml href="#S2.3">2.3</linkHtml>)</paragraph>
                                 </td>
                                 <td align="right" valign="top">
                                    <paragraph>01/2025</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Contraindications (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                                 </td>
                                 <td align="right" valign="top">
                                    <paragraph>02/2025</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_B0934FDD-6987-40BD-B71F-F0E00DD7AD3F">
               <id root="00dba644-046b-4778-bca4-5485ad53e971"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="Boxed Warning section"/>
               <title>WARNING: SIGNIFICANT DRUG INTERACTIONS WITH PAXLOVID </title>
               <text>
                  <list listType="unordered">
                     <item>
                        <caption></caption>
                        <content styleCode="bold">PAXLOVID includes ritonavir, a strong CYP3A inhibitor, which may lead to greater exposure of certain concomitant medications, resulting in potentially severe, life-threatening, or fatal events <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, and <linkHtml href="#S7">Drug Interactions (7)</linkHtml>].</content>
                        </content>
                     </item>
                     <item>
                        <caption></caption>
                        <content styleCode="bold">Prior to prescribing PAXLOVID: 1) Review all medications taken by the patient to assess potential drug-drug interactions with a strong CYP3A inhibitor like PAXLOVID and 2) Determine if concomitant medications require a dose adjustment, interruption, and/or additional monitoring <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>].</content>
                        </content>
                     </item>
                     <item>
                        <caption></caption>
                        <content styleCode="bold">Consider the benefit of PAXLOVID treatment in reducing hospitalization and death, and whether the risk of potential drug-drug interactions for an individual patient can be appropriately managed <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#S7">Drug Interactions (7)</linkHtml>, and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>].</content>
                        </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="_Toc195611240">WARNING: SIGNIFICANT DRUG INTERACTIONS WITH PAXLOVID </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption></caption>
                              <content styleCode="bold">PAXLOVID includes ritonavir, a strong CYP3A inhibitor, which may lead to greater exposure of certain concomitant medications, resulting in potentially severe, life-threatening, or fatal events. <content styleCode="italics">(<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S7">7</linkHtml>)</content>
                              </content>
                           </item>
                           <item>
                              <caption></caption>
                              <content styleCode="bold">Prior to prescribing PAXLOVID: 1) Review all medications taken by the patient to assess potential drug-drug interactions with a strong CYP3A inhibitor like PAXLOVID and 2) Determine if concomitant medications require a dose adjustment, interruption, and/or additional monitoring. <content styleCode="italics">(<linkHtml href="#S7">7</linkHtml>)</content>
                              </content>
                           </item>
                           <item>
                              <caption></caption>
                              <content styleCode="bold">Consider the benefit of PAXLOVID treatment in reducing hospitalization and death, and whether the risk of potential drug-drug interactions for an individual patient can be appropriately managed. <content styleCode="italics">(<linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S7">7</linkHtml>, <linkHtml href="#S14">14</linkHtml>)</content>
                              </content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="a811e6e5-0af7-492c-a306-54ec8e40c075"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>PAXLOVID is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.</paragraph>
               </text>
               <effectiveTime value="20230531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>PAXLOVID which includes nirmatrelvir, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M<sup>pro</sup>: also referred to as 3CL<sup>pro</sup> or nsp5 protease) inhibitor, and ritonavir, an HIV-1 protease inhibitor and CYP3A inhibitor, is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. (<linkHtml href="#S1">1</linkHtml>)<br/>
                           <br/>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <paragraph>PAXLOVID is not approved for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_af7b584a-2e80-47d1-ada9-22c4e6dd5e78">
                     <id root="4bf39c25-f11b-48c8-8a1c-54b258fd8e79"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <paragraph>PAXLOVID is not approved for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19 <content styleCode="italics">[see <linkHtml href="#S14.3">Clinical Studies (14.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="32d6a94a-0ce7-44b3-a8ed-bfc53c7bc0b8"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets. (<linkHtml href="#S2.1">2.1</linkHtml>)</paragraph>
                        <paragraph>Nirmatrelvir must be co-administered with ritonavir. (<linkHtml href="#S2.1">2.1</linkHtml>)</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption></caption>Initiate PAXLOVID treatment as soon as possible after diagnosis of COVID-19 and within 5 days of symptom onset. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>
                              <caption></caption>Administer orally with or without food. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>
                              <caption></caption>Administer at approximately the same time each day. (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>)</item>
                           <item>
                              <caption></caption>Dosage: 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet), with all 3 tablets taken together twice daily for 5 days. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>
                              <caption></caption>
                              <content styleCode="bold">Dose Reduction for Renal Impairment</content> (<linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S8.6">8.6</linkHtml>, <linkHtml href="#S12.3">12.3</linkHtml>)</item>
                        </list>
                        <table width="100%">
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">Abbreviation: eGFR=estimated glomerular filtration rate.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>
                                          <content styleCode="bold">Renal Function</content>
                                       </item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Days of Treatment</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>
                                          <content styleCode="bold">Dose and Dose Frequency</content>
                                          <footnote ID="_Ref189562050">PAXLOVID should be administered at approximately the same time each day for 5 days.</footnote>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>Moderate renal impairment (eGFR 30 to &lt;60 mL/min)</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>Days 1-5</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>150 mg nirmatrelvir (one 150 mg tablet) with 100 mg ritonavir (one 100 mg tablet) <content styleCode="bold">twice daily</content>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>Severe renal impairment (eGFR &lt;30 mL/min) including those requiring hemodialysis<footnote ID="_Ref189562111">On days of hemodialysis, the PAXLOVID dose should be administered after hemodialysis.</footnote>
                                       </item>
                                    </list>
                                 </td>
                                 <td align="center" valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>Day 1</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) <content styleCode="bold">once</content>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>Days 2-5</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>150 mg nirmatrelvir (one 150 mg tablet) with 100 mg ritonavir (one 100 mg tablet) <content styleCode="bold">once daily</content>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <list listType="unordered">
                           <item>
                              <caption></caption>PAXLOVID is not recommend in patients with severe hepatic impairment (Child-Pugh Class C). (<linkHtml href="#S2.4">2.4</linkHtml>, <linkHtml href="#S8.7">8.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="64ede963-8bf7-44f9-9a6f-a6db6ce21a29"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Important Dosage and Administration Information</title>
                     <text>
                        <paragraph>PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets. There are three different dose packs available:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption></caption>PAXLOVID (nirmatrelvir; ritonavir) co-packaged for oral use 300 mg;100 mg <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</item>
                           <item>
                              <caption></caption>PAXLOVID (nirmatrelvir; ritonavir) co-packaged for oral use 150 mg;100 mg for patients with moderate renal impairment <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>].</content>
                           </item>
                           <item>
                              <caption></caption>
                              <content styleCode="xmChange">PAXLOVID (nirmatrelvir; ritonavir) co-packaged for oral use 300 mg;100 mg (Day 1) and 150 mg;100 mg (Days 2-5) for patients with severe renal impairment <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]</content>.</content>
                           </item>
                        </list>
                        <paragraph>Nirmatrelvir must be co-administered with ritonavir. Failure to correctly co-administer nirmatrelvir with ritonavir may result in plasma levels of nirmatrelvir that are insufficient to achieve the desired therapeutic effect.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Prescriptions should specify the numeric dose of each active ingredient within PAXLOVID [see <linkHtml href="#S2.2">Dosage and Administration (2.2</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>)].</content> Completion of the full 5-day treatment course and continued isolation in accordance with public health recommendations are important to maximize viral clearance and minimize transmission of SARS-CoV-2.</paragraph>
                        <paragraph>The 5-day treatment course of PAXLOVID should be initiated as soon as possible after a diagnosis of COVID-19 has been made, and within 5 days of symptom onset even if baseline COVID-19 symptoms are mild. Should a patient require hospitalization due to severe or critical COVID-19 after starting treatment with PAXLOVID, the patient should complete the full 5-day treatment course per the healthcare provider's discretion.</paragraph>
                        <paragraph>If the patient misses a dose of PAXLOVID within 8 hours of the time it is usually taken, the patient should take it as soon as possible and resume the normal dosing schedule. If the patient misses a dose by more than 8 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. The patient should not double the dose to make up for a missed dose.</paragraph>
                        <paragraph>PAXLOVID (both nirmatrelvir and ritonavir tablets) can be taken with or without food <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. The tablets should be swallowed whole and not chewed, broken, or crushed.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="dc1eb699-1015-4e94-9ff4-c78006f88eac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Recommended Dosage</title>
                     <text>
                        <paragraph>The recommended dosage for PAXLOVID is 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all 3 tablets taken together orally twice daily in the morning and at bedtime for 5 days.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="82ef01e1-f262-4d76-8c05-fcc98efa2b7f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Dosage in Patients with Renal Impairment</title>
                     <text>
                        <paragraph>Prescriptions should specify the numeric dose of each active ingredient within PAXLOVID. Providers should counsel patients about renal dosing instructions <content styleCode="italics">[see <linkHtml href="#S17">Patient Counseling Information (17)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">No dosage adjustment is </content>recommended in patients <content styleCode="xmChange">with mild renal impairment [estimated glomerular filtration rate (eGFR) 60 to &lt;90 mL/min].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">In patients with moderate renal impairment (eGFR 30 to &lt;60 mL/min) or </content>with severe renal impairment (eGFR &lt;30 mL/min)<content styleCode="xmChange"> including those requiring hemodialysis, the dosage of PAXLOVID should be reduced as shown in Table 1. PAXLOVID should be administered at approximately the same time each day for 5 days. On days </content>patients with severe renal impairment<content styleCode="xmChange"> undergo hemodialysis, the PAXLOVID dose should be administered after hemodialysis <content styleCode="italics">[see <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>, and <linkHtml href="#S16">How Supplied/Storage and Handling (16)</linkHtml>]</content>.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="bold">Table 1:	Recommended Dose and Regimen for Patients with Renal Impairment</content>
                           </content>
                        </paragraph>
                        <table width="100%">
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <content styleCode="xmChange">Abbreviation: eGFR=estimated glomerular filtration rate.</content>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">Renal Function</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">Days of Treatment</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">
                                          <content styleCode="bold">Dose and Dose Frequency<footnote ID="_Ref189564260">
                                                <content styleCode="xmChange">PAXLOVID should be administered at approximately the same time each day for 5 days.</content>
                                             </footnote>
                                          </content>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">Moderate renal impairment (eGFR 30 to &lt;60 mL/min)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">Days 1-5</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">150 mg nirmatrelvir (one 150 mg tablet) with 100 mg ritonavir (one 100 mg tablet) <content styleCode="bold">twice daily</content>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">Severe renal impairment (eGFR &lt;30 mL/min) including those requiring hemodialysis<footnote ID="_Ref189566070">
                                             <content styleCode="xmChange">On days of hemodialysis, the PAXLOVID dose should be administered after hemodialysis.</content>
                                          </footnote>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">Day 1</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) <content styleCode="bold">once</content>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">Days 2-5</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>
                                       <content styleCode="xmChange">150 mg nirmatrelvir (one 150 mg tablet) with 100 mg ritonavir (one 100 mg tablet) <content styleCode="bold">once daily</content>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250212"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="9cf5bc7b-fb94-478c-bd19-2cde25096893"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4	Use in Patients with Hepatic Impairment</title>
                     <text>
                        <paragraph>No dosage adjustment is needed in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.</paragraph>
                        <paragraph>No pharmacokinetic or safety data are available regarding the use of nirmatrelvir or ritonavir in subjects with severe (Child-Pugh Class C) hepatic impairment; therefore, PAXLOVID is not recommended for use in patients with severe hepatic impairment <content styleCode="italics">[see <linkHtml href="#S8.7">Use in Specific Populations (8.7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="6f1aad9a-0e6a-43ef-965a-2d8eaab81efe"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets <content styleCode="italics">[see <linkHtml href="#S16">How Supplied/Storage and Handling (16)</linkHtml>]</content>.</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption></caption>Nirmatrelvir is supplied as oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side. Each tablet contains 150 mg of nirmatrelvir.</item>
                     <item>
                        <caption></caption>Ritonavir is supplied as white or white to off-white film-coated tablets uniquely identified by the color, shape, and debossing. Each tablet contains 100 mg of ritonavir.</item>
                  </list>
               </text>
               <effectiveTime value="20230531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption></caption>Tablets: nirmatrelvir 150 mg (<linkHtml href="#S3">3</linkHtml>)</item>
                           <item>
                              <caption></caption>Tablets: ritonavir 100 mg (<linkHtml href="#S3">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="3ab42d0d-3b5d-4e21-be4e-1e55fadbb26e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>PAXLOVID is contraindicated in patients with a history of clinically significant hypersensitivity reactions [e.g., toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome] to its active ingredients (nirmatrelvir or ritonavir) or any other components of the product.</paragraph>
                  <paragraph>PAXLOVID is contraindicated with drugs that are primarily metabolized by CYP3A and for which elevated concentrations are associated with serious and/or life-threatening reactions and drugs that are strong CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance. There are certain other drugs for which concomitant use with PAXLOVID should be avoided and/or dose adjustment, interruption, or therapeutic monitoring is recommended. Drugs listed in this section are a guide and not considered a comprehensive list of all drugs that may be contraindicated with PAXLOVID. The healthcare provider should consult other appropriate resources such as the prescribing information for the interacting drug for comprehensive information on dosing or monitoring with concomitant use of a strong CYP3A inhibitor like PAXLOVID <content styleCode="italics">[see <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>]</content>:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption></caption>Drugs that are primarily metabolized by CYP3A for which elevated concentrations are associated with serious and/or life-threatening reactions <content styleCode="italics">[see <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>]</content>:<list listType="unordered">
                           <item>
                              <caption></caption>Alpha 1-adrenoreceptor antagonist: alfuzosin</item>
                           <item>
                              <caption></caption>Antianginal: ranolazine</item>
                           <item>
                              <caption></caption>Antiarrhythmic: amiodarone, dronedarone, flecainide, propafenone, quinidine</item>
                           <item>
                              <caption></caption>Anti-gout: colchicine (in patients with renal and/or hepatic impairment <content styleCode="italics">[see </content>
                              <content styleCode="italics">
                                 <linkHtml href="#Table2">Table 2</linkHtml>
                              </content>
                              <content styleCode="italics">, <linkHtml href="#S7.3">Drug Interactions (7.3)]</linkHtml>
                              </content>)</item>
                           <item>
                              <caption></caption>Antipsychotics: lurasidone, pimozide</item>
                           <item>
                              <caption></caption>Benign prostatic hyperplasia agents: silodosin</item>
                           <item>
                              <caption></caption>Cardiovascular agents: eplerenone, ivabradine</item>
                           <item>
                              <caption></caption>Ergot derivatives: dihydroergotamine, ergotamine, methylergonovine</item>
                           <item>
                              <caption></caption>HMG-CoA reductase inhibitors: lovastatin, simvastatin (these drugs can be temporarily discontinued to allow PAXLOVID use <content styleCode="italics">[see </content>
                              <content styleCode="italics">
                                 <linkHtml href="#Table2">Table 2</linkHtml>
                              </content>
                              <content styleCode="italics">, <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>]</content>)</item>
                           <item>
                              <caption></caption>Immunosuppressants: voclosporin</item>
                           <item>
                              <caption></caption>Microsomal triglyceride transfer protein inhibitor: lomitapide</item>
                           <item>
                              <caption></caption>Migraine medications: eletriptan, ubrogepant</item>
                           <item>
                              <caption></caption>Mineralocorticoid receptor antagonists: finerenone</item>
                           <item>
                              <caption></caption>Opioid antagonists: naloxegol</item>
                           <item>
                              <caption></caption>PDE5 inhibitor: sildenafil (Revatio<sup></sup>) when used for pulmonary arterial hypertension (PAH)</item>
                           <item>
                              <caption></caption>Sedative/hypnotics: triazolam, oral midazolam</item>
                           <item>
                              <caption></caption>Serotonin receptor 1A agonist/serotonin receptor 2A antagonist: flibanserin</item>
                           <item>
                              <caption></caption>Vasopressin receptor antagonists: tolvaptan</item>
                        </list>
                     </item>
                     <item>
                        <caption></caption>Drugs that are strong CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance. PAXLOVID cannot be started immediately after discontinuation of any of the following medications due to the delayed offset of the recently discontinued CYP3A inducer <content styleCode="italics">[see <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>]</content>:<list listType="unordered">
                           <item>
                              <caption></caption>Anticancer drugs: apalutamide<content styleCode="xmChange">, enzalutamide</content>
                           </item>
                           <item>
                              <caption></caption>Anticonvulsant: carbamazepine, phenobarbital, primidone, phenytoin</item>
                           <item>
                              <caption></caption>Antimycobacterials: rifampin, rifapentine</item>
                           <item>
                              <caption></caption>Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor</item>
                           <item>
                              <caption></caption>Herbal products: St. John's Wort (<content styleCode="italics">hypericum perforatum</content>)</item>
                        </list>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption></caption>History of clinically significant hypersensitivity reactions to the active ingredients (nirmatrelvir or ritonavir) or any other components. (<linkHtml href="#S4">4</linkHtml>)</item>
                           <item>
                              <caption></caption>Co-administration with drugs highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S7.3">7.3</linkHtml>)</item>
                           <item>
                              <caption></caption>Co-administration with potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance. (<linkHtml href="#S4">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="e1a6bcce-228d-43e3-a1af-2dddaf8784b1"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption></caption>The concomitant use of PAXLOVID and certain other drugs may result in potentially significant drug interactions. Consult the Full Prescribing Information prior to and during treatment for potential drug interactions. (<linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S7">7</linkHtml>)</item>
                           <item>
                              <caption></caption>Hypersensitivity Reactions: Anaphylaxis, serious skin reactions (including toxic epidermal necrolysis and Stevens-Johnson syndrome), and other hypersensitivity reactions have been reported with PAXLOVID. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue PAXLOVID and initiate appropriate medications and/or supportive care. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>
                              <caption></caption>Hepatotoxicity: Hepatic transaminase elevations, clinical hepatitis, and jaundice have occurred in patients receiving ritonavir. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>
                              <caption></caption>HIV-1 Drug Resistance: PAXLOVID use may lead to a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection. (<linkHtml href="#S5.4">5.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="15f57e85-d9dc-4825-8a5a-e3ac425f7473"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Risk of Serious Adverse Reactions Due to Drug Interactions</title>
                     <text>
                        <paragraph>Initiation of PAXLOVID, which contains ritonavir, a strong CYP3A inhibitor, in patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving PAXLOVID, may increase plasma concentrations of medications metabolized by CYP3A. Medications that induce CYP3A may decrease concentrations of PAXLOVID. These interactions may lead to:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption></caption>Clinically significant adverse reactions, potentially leading to severe, life-threatening, or fatal events from greater exposures of concomitant medications.</item>
                           <item>
                              <caption></caption>Loss of therapeutic effect of PAXLOVID and possible development of viral resistance.</item>
                        </list>
                        <paragraph>Severe, life-threatening, and/or fatal adverse reactions due to drug interactions have been reported in patients treated with PAXLOVID. The most commonly reported concomitant medications resulting in serious adverse reactions were calcineurin inhibitors (e.g., tacrolimus, cyclosporine), followed by calcium channel blockers. </paragraph>
                        <paragraph>Prior to prescribing PAXLOVID, review all medications taken by the patient to assess potential drug-drug interactions and determine if concomitant medications require a dose adjustment, interruption, and/or additional monitoring (e.g., calcineurin inhibitors) <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml> and <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>. See <linkHtml href="#Table2">Table 2</linkHtml> for clinically significant drug interactions, including contraindicated drugs. Drugs listed in Table 2 are a guide and not considered a comprehensive list of all possible drugs that may interact with PAXLOVID.</paragraph>
                        <paragraph>Consider the benefit of PAXLOVID treatment in reducing hospitalization and death, and whether the risk of potential drug-drug interactions for an individual patient can be appropriately managed <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml> and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="d2a3a397-9864-4c3a-8813-1f1a62159436"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Anaphylaxis, serious skin reactions (including toxic epidermal necrolysis and Stevens-Johnson syndrome), and other hypersensitivity reactions have been reported with PAXLOVID <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].</content> If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue PAXLOVID and initiate appropriate medications and/or supportive care.</paragraph>
                     </text>
                     <effectiveTime value="20230531"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="169eadf0-da84-4517-bfa4-eca559c66cbc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Hepatotoxicity</title>
                     <text>
                        <paragraph>Hepatic transaminase elevations, clinical hepatitis, and jaundice have occurred in patients receiving ritonavir. Therefore, caution should be exercised when administering PAXLOVID to patients with pre-existing liver diseases, liver enzyme abnormalities, or hepatitis.</paragraph>
                     </text>
                     <effectiveTime value="20230531"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="8b457df7-e1f3-4412-80af-d9996c50bb3a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Risk of HIV-1 Resistance Development</title>
                     <text>
                        <paragraph>Because nirmatrelvir is co-administered with ritonavir, there may be a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml> and <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="e1a11387-656f-409a-86dd-885d1ba27d71"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption></caption>Hypersensitivity reactions <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence 1% and greater incidence than in the placebo group) are dysgeusia and diarrhea. (<linkHtml href="#S6.1">6.1</linkHtml>)<br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="5ed7b01f-0e37-4afb-9367-4017d3d66393"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1	Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The safety of PAXLOVID is based on two Phase 2/3 randomized, placebo-controlled trials in symptomatic adult subjects 18 years of age and older with a laboratory confirmed diagnosis of SARS-CoV-2 infection. Subjects in both studies received PAXLOVID (nirmatrelvir/ritonavir 300 mg/100 mg) or placebo every 12 hours for 5 days for the treatment of mild-to-moderate COVID-19 within 5 days of symptom onset <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption></caption>Trial C4671005 (EPIC-HR) enrolled subjects who were at high risk for progression to severe disease. </item>
                           <item>
                              <caption></caption>Trial C4671002 (EPIC-SR) enrolled subjects who were at standard risk for progression to severe disease (previously unvaccinated subjects at standard risk or fully vaccinated subjects with at least 1 risk factor for progression to severe disease). </item>
                        </list>
                        <paragraph>Adverse reactions were those reported while subjects were on study medication and through 28 days after the last dose of study treatment. </paragraph>
                        <paragraph>In Trial C4671005 (EPIC-HR), 1,038 subjects received PAXLOVID and 1,053 subjects received placebo. The most common adverse reactions (1% incidence in the PAXLOVID group and occurring at a greater frequency than in the placebo group) were dysgeusia (5% and &lt;1%, respectively) and diarrhea (3% and 2%, respectively).</paragraph>
                        <paragraph>Among vaccinated or unvaccinated subjects at standard risk or fully vaccinated subjects with at least 1 risk factor for progression to severe disease in Trial C4671002 (EPIC-SR), 540 subjects received PAXLOVID and 528 subjects received placebo. The adverse reactions observed were consistent with those observed in EPIC-HR.</paragraph>
                        <paragraph>Trial C4671028 (EPIC-SRI) was a Phase 1, open-label trial that evaluated the effects of severe renal impairment on the pharmacokinetics, safety, and tolerability of PAXLOVID in non-hospitalized adult participants with COVID-19 and severe renal impairment. A total of 15 subjects with severe renal impairment were enrolled in this trial, with 12 subjects receiving intermittent hemodialysis and 3 subjects not on hemodialysis. Subjects received nirmatrelvir/ritonavir 300 mg/100 mg once on Day 1 followed by nirmatrelvir/ritonavir 150 mg/100 mg once daily from Days 2-5. The safety profile of PAXLOVID in subjects with severe renal impairment, including those requiring hemodialysis, was consistent with the safety profile observed in the Phase 2/3 randomized, placebo-controlled trials.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Emergency Use Authorization Experience in Subjects with COVID-19</content>
                        </paragraph>
                        <paragraph>The following adverse reactions have been identified during use of PAXLOVID under Emergency Use Authorization.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune System Disorders:</content> Anaphylaxis, hypersensitivity reactions <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous Tissue Disorders:</content> Toxic epidermal necrolysis, Stevens-Johnson syndrome <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders:</content> Headache</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular Disorders:</content> Hypertension</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders:</content> Abdominal pain, nausea, vomiting</paragraph>
                        <paragraph>
                           <content styleCode="italics">General Disorders and Administration Site Conditions:</content> Malaise</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="7eeebee4-01b0-4e62-89a0-70bab75b6715"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Co-administration of PAXLOVID can alter the plasma concentrations of other drugs and other drugs may alter the plasma concentrations of PAXLOVID. Consider the potential for drug interactions prior to and during PAXLOVID therapy and review concomitant medications during PAXLOVID therapy. (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S7">7</linkHtml>, <linkHtml href="#S12.3">12.3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="6d2453a9-4d20-4850-868a-3c17d9957382"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	Potential for PAXLOVID to Affect Other Drugs</title>
                     <text>
                        <paragraph>PAXLOVID (nirmatrelvir co-packaged with ritonavir) is a strong inhibitor of CYP3A, and an inhibitor of CYP2D6, P-gp and OATP1B1. Co-administration of PAXLOVID with drugs that are primarily metabolized by CYP3A and CYP2D6 or are transported by P-gp or OATP1B1 may result in increased plasma concentrations of such drugs and increase the risk of adverse events. Co-administration of PAXLOVID with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml> and <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml></content>
                           <content styleCode="italics">
                              <linkHtml href="#Table2">Table 2</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>. Co-administration with other CYP3A substrates may require a dose adjustment or additional monitoring as shown in Table 2.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="a0658b29-532a-4462-9398-5974dfa7ab24"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2	Potential for Other Drugs to Affect PAXLOVID</title>
                     <text>
                        <paragraph>Nirmatrelvir and ritonavir are CYP3A substrates; therefore, drugs that induce CYP3A may decrease nirmatrelvir and ritonavir plasma concentrations and reduce PAXLOVID therapeutic effect <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml> and <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml></content>
                           <content styleCode="italics">
                              <linkHtml href="#Table2">Table 2</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="08cc4f4d-da39-4f7c-9ecb-25ad4f41feb0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3	Established and Other Potentially Significant Drug Interactions</title>
                     <text>
                        <paragraph>Table 2 provides a listing of clinically significant drug interactions, including contraindicated drugs <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml> and <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>. Drugs listed in Table 2 are a guide and not considered a comprehensive list of all possible drugs that may interact with PAXLOVID. The healthcare provider should consult other appropriate resources such as the prescribing information for the interacting drug for comprehensive information on dosing or monitoring with concomitant use of a strong CYP3A inhibitor such as ritonavir.</paragraph>
                        <table ID="Table2" styleCode="Noautorules" width="95%">
                           <caption>Table 2:	Established and Other Potentially Significant Drug Interactions</caption>
                           <col width="21%"/>
                           <col width="24%"/>
                           <col width="21%"/>
                           <col width="34%"/>
                           <thead>
                              <tr>
                                 <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <content styleCode="bold">Drug Class</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <content styleCode="bold">Drugs within Class</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <content styleCode="bold">Effect on Concentration</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <content styleCode="bold">Clinical Comments</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Alpha 1-<br/>adrenoreceptor antagonist</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>alfuzosin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> alfuzosin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration contraindicated due to potential hypotension <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Alpha 1-<br/>adrenoreceptor antagonist</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>tamsulosin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> tamsulosin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Avoid concomitant use with PAXLOVID.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Antianginal</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>ranolazine</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> ranolazine</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration contraindicated due to potential for serious and/or life-threatening reactions <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Antiarrhythmics</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>amiodarone, <br/>dronedarone, <br/>flecainide, <br/>propafenone, <br/>quinidine</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> antiarrhythmic</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration contraindicated due to potential for cardiac arrhythmias <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Antiarrhythmics</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>lidocaine (systemic),<br/>disopyramide</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> antiarrhythmic</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics if available.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Anticancer drugs</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>apalutamide, </paragraph>
                                    <paragraph>enzalutamide</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> nirmatrelvir/ritonavir</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration contraindicated due to potential loss of virologic response and possible resistance <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>].</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Anticancer drugs</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>abemaciclib, <br/>ceritinib,<br/>dasatinib, <br/>encorafenib,<br/>ibrutinib, <br/>ivosidenib, <br/>neratinib, <br/>nilotinib, <br/>venetoclax,<br/>vinblastine, <br/>vincristine</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> anticancer drugs</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Avoid co-administration of encorafenib or ivosidenib due to potential risk of serious adverse events such as QT interval prolongation. Avoid use of neratinib, venetoclax or ibrutinib.<br/>
                                       <br/>Co-administration of vincristine and vinblastine may lead to significant hematologic or gastrointestinal side effects.<br/>
                                       <br/>For further information, refer to individual product label for anticancer drug.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Anticoagulants </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>warfarin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> warfarin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Closely monitor international normalized ratio (INR) if co-administration with warfarin is necessary.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>rivaroxaban</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> rivaroxaban</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Increased bleeding risk with rivaroxaban. Avoid concomitant use.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>dabigatran<footnote ID="_Reft1fa">See <linkHtml href="#S12.3">Pharmacokinetics, Clinical Drug Interaction Studies (12.3)</linkHtml>.</footnote>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> dabigatran</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Increased bleeding risk with dabigatran. Depending on dabigatran indication and renal function, reduce dose of dabigatran or avoid concomitant use. Refer to the dabigatran product label for further information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>apixaban</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> apixaban</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Combined P-gp and strong CYP3A inhibitors increase blood levels of apixaban and increase the risk of bleeding. Dosing recommendations for co-administration of apixaban with PAXLOVID depend on the apixaban dose. Refer to the apixaban product label for more information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Anticonvulsants</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>carbamazepine<footnoteRef IDREF="_Reft1fa"/>,<br/>phenobarbital,<br/>primidone,<br/>phenytoin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> nirmatrelvir/ritonavir</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration contraindicated due to potential loss of virologic response and possible resistance <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Anticonvulsants</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>clonazepam</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> anticonvulsant</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>A dose decrease may be needed for clonazepam when co-administered with PAXLOVID and clinical monitoring is recommended.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Antidepressants</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>bupropion</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> bupropion and active metabolite hydroxy-bupropion </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Monitor for an adequate clinical response to bupropion. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>trazodone</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> trazodone</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Adverse reactions of nausea, dizziness, hypotension, and syncope have been observed following co-administration of trazodone and ritonavir. A lower dose of trazodone should be considered. Refer to trazadone product label for further information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Antifungals</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>voriconazole</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> voriconazole</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Avoid concomitant use of voriconazole.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>ketoconazole, <br/>isavuconazonium sulfate,<br/>itraconazole<footnoteRef IDREF="_Reft1fa"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> ketoconazole<br/> isavuconazonium sulfate<br/> itraconazole</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Refer to ketoconazole, isavuconazonium sulfate, and itraconazole product labels for further information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> nirmatrelvir/ritonavir</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>A nirmatrelvir/ritonavir dose reduction is not needed.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Anti-gout</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>colchicine</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> colchicine</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration contraindicated due to potential for serious and/or life-threatening reactions in patients with renal and/or hepatic impairment <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Anti-HIV protease inhibitors</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>atazanavir,<br/>darunavir,<br/>tipranavir</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> protease inhibitor</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>For further information, refer to the respective protease inhibitors' prescribing information.<br/>
                                       <br/>Patients on ritonavir- or cobicistat-containing HIV regimens should continue their treatment as indicated. Monitor for increased PAXLOVID or protease inhibitor adverse events<content styleCode="italics">.</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Anti-HIV</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>efavirenz,<br/>maraviroc,<br/>nevirapine,<br/>zidovudine,<br/>bictegravir/ <br/>emtricitabine/ <br/>tenofovir</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> efavirenz<br/> maraviroc<br/> nevirapine<br/> zidovudine<br/> bictegravir<br/> emtricitabine<br/> tenofovir</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>For further information, refer to the respective anti-HIV drugs prescribing information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Anti-infective</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>clarithromycin,<br/>erythromycin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> clarithromycin<br/> erythromycin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Refer to the respective prescribing information for anti-infective dose adjustment.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Antimycobacterial</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>rifampin,<br/>rifapentine</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> nirmatrelvir/ritonavir</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration contraindicated due to potential loss of virologic response and possible resistance. Alternate antimycobacterial drugs such as rifabutin should be considered <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Antimycobacterial</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>bedaquiline</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> bedaquiline</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Refer to the bedaquiline product label for further information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>rifabutin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> rifabutin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Refer to rifabutin product label for further information on rifabutin dose reduction.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Antipsychotics</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>lurasidone,<br/>pimozide</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> lurasidone<br/> pimozide</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration contraindicated due to serious and/or life-threatening reactions such as cardiac arrhythmias <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Antipsychotics</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>quetiapine</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> quetiapine</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>If co-administration is necessary, reduce quetiapine dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine prescribing information for recommendations.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>clozapine</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> clozapine</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>If co-administration is necessary, consider reducing the clozapine dose and monitor for adverse reactions.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Benign prostatic hyperplasia agents</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>silodosin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> silodosin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration contraindicated due to potential for postural hypotension <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Calcium channel blockers</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>amlodipine, <br/>diltiazem,<br/>felodipine,<br/>nicardipine,<br/>nifedipine,<br/>verapamil</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> calcium channel blocker</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Caution is warranted and clinical monitoring of patients is recommended. A dose decrease may be needed for these drugs when co-administered with PAXLOVID.<br/>
                                       <br/>If co-administered, refer to individual product label for calcium channel blocker for further information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Cardiac glycosides</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>digoxin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> digoxin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Caution should be exercised when co-administering PAXLOVID with digoxin, with appropriate monitoring of serum digoxin levels.<br/>
                                       <br/>Refer to the digoxin product label for further information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Cardiovascular agents</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>eplerenone</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> eplerenone</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration with eplerenone is contraindicated due to potential for hyperkalemia <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>ivabradine</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> ivabradine</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration with ivabradine is contraindicated due to potential for bradycardia or conduction disturbances <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Cardiovascular agents</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>aliskiren,<br/>ticagrelor,<br/>vorapaxar<br/>
                                       <br/>clopidogrel</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> aliskiren<br/> ticagrelor<br/> vorapaxar<br/>
                                       <br/> clopidogrel active metabolite</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Avoid concomitant use with PAXLOVID.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>cilostazol</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> cilostazol</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Dosage adjustment of cilostazol is recommended. Refer to the cilostazol product label for more information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Corticosteroids primarily metabolized by CYP3A</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>betamethasone,<br/>budesonide,<br/>ciclesonide,<br/>dexamethasone,<br/>fluticasone,<br/>methylprednisolone,<br/>mometasone,<br/>triamcinolone</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> corticosteroid</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration with corticosteroids (all routes of administration) of which exposures are significantly increased by strong CYP3A inhibitors can increase the risk for Cushings syndrome and adrenal suppression. However, the risk of Cushings syndrome and adrenal suppression associated with short-term use of a strong CYP3A inhibitor is low.<br/>
                                       <br/>Alternative corticosteroids including beclomethasone, prednisone, and prednisolone should be considered.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Cystic fibrosis transmembrane conductance regulator potentiators</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>lumacaftor/ivacaftor</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> nirmatrelvir/ritonavir</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration contraindicated due to potential loss of virologic response and possible resistance <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>].</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Cystic fibrosis transmembrane conductance regulator potentiators</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>ivacaftor<br/>elexacaftor/tezacaftor/<br/>ivacaftor<br/>
                                       <br/>tezacaftor/ivacaftor</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> ivacaftor<br/> elexacaftor/tezacaftor/<br/>ivacaftor<br/>
                                       <br/> tezacaftor/ivacaftor</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Reduce dosage when co-administered with PAXLOVID. Refer to individual product labels for more information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Dipeptidyl peptidase 4 (DPP4) inhibitors</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>saxagliptin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> saxagliptin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Dosage adjustment of saxagliptin is recommended. Refer to the saxagliptin product label for more information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Endothelin receptor antagonists</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>bosentan</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> bosentan<br/> nirmatrelvir/ritonavir</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Discontinue use of bosentan at least 36 hours prior to initiation of PAXLOVID.<br/>
                                       <br/>Refer to the bosentan product label for further information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Ergot derivatives</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>dihydroergotamine,<br/>ergotamine,<br/>methylergonovine</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> dihydroergotamine<br/> ergotamine<br/> methylergonovine</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration contraindicated due to potential for acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Hepatitis C direct acting antivirals</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>elbasvir/grazoprevir</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> antiviral</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Increased grazoprevir concentrations can result in alanine transaminase (ALT) elevations.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>glecaprevir/pibrentasvir</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Avoid concomitant use of glecaprevir/pibrentasvir with PAXLOVID.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>ombitasvir/paritaprevir/ ritonavir and dasabuvir</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Refer to the ombitasvir/paritaprevir/ritonavir and dasabuvir label for further information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>sofosbuvir/velpatasvir/ voxilaprevir</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Refer to the sofosbuvir/velpatasvir/voxilaprevir product label for further information.<br/>Patients on ritonavir-containing HCV regimens should continue their treatment as indicated. Monitor for increased PAXLOVID or HCV drug adverse events with concomitant use<content styleCode="italics">.</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Herbal products</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>St. John's Wort (<content styleCode="italics">hypericum perforatum</content>)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> nirmatrelvir/ritonavir</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration contraindicated due to potential loss of virologic response and possible resistance <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>HMG-CoA reductase inhibitors</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>lovastatin,<br/>simvastatin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> lovastatin<br/> simvastatin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration contraindicated due to potential for myopathy including rhabdomyolysis <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.<br/>
                                       <br/>If treatment with PAXLOVID is considered medically necessary, discontinue use of lovastatin and simvastatin at least 12 hours prior to initiation of PAXLOVID, during the 5 days of PAXLOVID treatment, and for 5 days after completing PAXLOVID.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>HMG-CoA reductase inhibitors</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>atorvastatin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> atorvastatin<br/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Consider temporary discontinuation of atorvastatin during treatment with PAXLOVID. Atorvastatin does not need to be withheld prior to or after completing PAXLOVID.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Hormonal contraceptive</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>ethinyl estradiol</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> ethinyl estradiol</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>An additional, non-hormonal method of contraception should be considered during the 5 days of PAXLOVID treatment and until one menstrual cycle after stopping PAXLOVID.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Immunosuppressants</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>voclosporin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> voclosporin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration contraindicated due to potential for acute and/or chronic nephrotoxicity <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Immunosuppressants</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>calcineurin inhibitors:<br/>cyclosporine,<br/>tacrolimus</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <br/> cyclosporine<br/> tacrolimus</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Avoid concomitant use of calcineurin inhibitors with PAXLOVID when close monitoring of immunosuppressant concentrations is not feasible. If co-administered, dose adjustment of the immunosuppressant and close and regular monitoring for immunosuppressant concentrations and adverse reactions are recommended during and after treatment with PAXLOVID. Obtain expert consultation to appropriately manage the complexity of this co-administration <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>mTOR inhibitors:<br/>everolimus,<br/>sirolimus</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <br/> everolimus<br/> sirolimus</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <br/>Avoid concomitant use of everolimus and sirolimus and PAXLOVID.<br/>
                                       <br/>Refer to the individual immunosuppressant product label and latest guidelines for further information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Janus kinase (JAK) inhibitors</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>tofacitinib</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> tofacitinib</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Dosage adjustment of tofacitinib is recommended. Refer to the tofacitinib product label for more information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>upadacitinib</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> upadacitinib</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Dosing recommendations for co-administration of upadacitinib with PAXLOVID depends on the upadacitinib indication. Refer to the upadacitinib product label for more information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Long-acting beta-adrenoceptor agonist</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>salmeterol</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> salmeterol</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Avoid concomitant use with PAXLOVID. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Microsomal triglyceride transfer protein (MTTP) inhibitor</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>lomitapide</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> lomitapide</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration contraindicated due to potential for hepatotoxicity and gastrointestinal adverse reactions <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Migraine medications</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>eletriptan</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> eletriptan</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration of eletriptan within at least 72 hours of PAXLOVID is contraindicated due to potential for serious adverse reactions including cardiovascular and cerebrovascular events <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>ubrogepant</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> ubrogepant</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration of ubrogepant with PAXLOVID is contraindicated due to potential for serious adverse reactions <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Migraine medications</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>rimegepant</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> rimegepant</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Avoid concomitant use with PAXLOVID.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Mineralocorticoid receptor antagonists</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>finerenone</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> finerenone</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration contraindicated due to potential for serious adverse reactions including hyperkalemia, hypotension, and hyponatremia <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Muscarinic receptor antagonists</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>darifenacin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> darifenacin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>The darifenacin daily-dose should not exceed 7.5 mg when co-administered with PAXLOVID. Refer to the darifenacin product label for more information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Narcotic analgesics</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>fentanyl,<br/>hydrocodone,<br/>oxycodone,<br/>meperidine</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> fentanyl<br/> hydrocodone<br/> oxycodone<br/> meperidine</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Careful monitoring of therapeutic and adverse effects (including potentially fatal respiratory depression) is recommended when fentanyl, hydrocodone, oxycodone, or meperidine is concomitantly administered with PAXLOVID. If concomitant use with PAXLOVID is necessary, consider a dosage reduction of the narcotic analgesic and monitor patients closely at frequent intervals. Refer to the individual product label for more information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>methadone</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> methadone</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Monitor methadone-maintained patients closely for evidence of withdrawal effects and adjust the methadone dose accordingly.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Neuropsychiatric agents</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>suvorexant</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> suvorexant</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Avoid concomitant use of suvorexant with PAXLOVID.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>aripiprazole,<br/>brexpiprazole,<br/>cariprazine,<br/>iloperidone,<br/>lumateperone,<br/>pimavanserin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> aripiprazole<br/> brexpiprazole<br/> cariprazine<br/> iloperidone<br/> lumateperone<br/> pimavanserin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Dosage adjustment of aripiprazole, brexpiprazole, cariprazine, iloperidone, lumateperone, and pimavanserin is recommended. Refer to individual product label for more information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Opioid antagonists</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>naloxegol</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> naloxegol</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration contraindicated due to the potential for opioid withdrawal symptoms <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Pulmonary hypertension agents (PDE5 inhibitors)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>sildenafil (Revatio<sup></sup>)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> sildenafil</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration of sildenafil with PAXLOVID is contraindicated for use in pulmonary hypertension due to the potential for sildenafil associated adverse events, including visual abnormalities hypotension, prolonged erection, and syncope <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Pulmonary hypertension agents (PDE5 inhibitors)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>tadalafil (Adcirca<sup></sup>)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> tadalafil</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Avoid concomitant use of tadalafil with PAXLOVID for pulmonary hypertension.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Pulmonary hypertension agents (sGC stimulators)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>riociguat</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> riociguat</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Dosage adjustment is recommended for riociguat when used for pulmonary hypertension. Refer to the riociguat product label for more information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Erectile dysfunction agents (PDE5 inhibitors)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>avanafil</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> avanafil</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Do not use PAXLOVID with avanafil because a safe and effective avanafil dosage regimen has not been established.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>sildenafil,<br/>tadalafil,<br/>vardenafil</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> sildenafil<br/> tadalafil<br/> vardenafil</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Dosage adjustment is recommended for use of sildenafil, tadalafil or vardenafil with PAXLOVID when used for erectile dysfunction. Refer to individual product label for more information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Sedative/hypnotics </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>triazolam, <br/>oral midazolam<footnoteRef IDREF="_Reft1fa"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> triazolam<br/> midazolam</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration contraindicated due to potential for extreme sedation and respiratory depression <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Sedative/hypnotics</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>buspirone,<br/>clorazepate,<br/>diazepam,<br/>estazolam,<br/>flurazepam,<br/>zolpidem</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> sedative/hypnotic</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>A dose decrease may be needed for these drugs when co-administered with PAXLOVID and monitoring for adverse events.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>midazolam (administered parenterally)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> midazolam</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration of midazolam (parenteral) should be done in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered.<br/>
                                       <br/>Refer to the midazolam product label for further information.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Serotonin receptor 1A agonist/ serotonin receptor 2A antagonist</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>flibanserin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> flibanserin</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Co-administration contraindicated due to potential for hypotension, syncope, and CNS depression <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Vasopressin receptor antagonists</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>tolvaptan</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph> tolvaptan</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Co-administration contraindicated due to potential for dehydration, hypovolemia and hyperkalemia <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250212"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="1c30b44a-8bc7-41b6-8bdc-c93111793a78"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250131"/>
               <component>
                  <section ID="S8.1">
                     <id root="22db8d23-139e-42a8-bd41-ba2b094d3f24"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20230531"/>
                     <component>
                        <section ID="ID_3a20cfa5-f047-4fa2-93d3-39895a5f87ee">
                           <id root="29596331-b13e-419f-be13-539078d05679"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Available data on the use of nirmatrelvir during pregnancy are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Published observational studies on ritonavir use in pregnant women have not identified an increase in the risk of major birth defects. Published studies with ritonavir are insufficient to identify a drug associated risk of miscarriage <content styleCode="italics">(see <linkHtml href="#refdata">Data</linkHtml>).</content> There are maternal and fetal risks associated with untreated COVID-19 in pregnancy <content styleCode="italics">(see <linkHtml href="#refclinical">Clinical Considerations</linkHtml>).</content>
                              </paragraph>
                              <paragraph>In an embryo-fetal development study with nirmatrelvir, reduced fetal body weights following oral administration of nirmatrelvir to pregnant rabbits were observed at systemic exposures (AUC) approximately 11 times higher than clinical exposure at the approved human dose of PAXLOVID. No other adverse developmental outcomes were observed in animal reproduction studies with nirmatrelvir at systemic exposures (AUC) greater than or equal to 3 times higher than clinical exposure at the approved human dose of PAXLOVID <content styleCode="italics">(see <linkHtml href="#refdata">Data</linkHtml>)</content>.</paragraph>
                              <paragraph>In embryo-fetal developmental studies with ritonavir, no evidence of adverse developmental outcomes was observed following oral administration of ritonavir to pregnant rats and rabbits at systemic exposures (AUC) 5 (rat) or 8 (rabbits) times higher than clinical exposure at the approved human dose of PAXLOVID <content styleCode="italics">(see <linkHtml href="#refdata">Data</linkHtml>)</content>.</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20230531"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Clinical">
                           <id root="38333b1d-a4e5-4d59-a399-19cae772c1a4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="refclinical">
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230531"/>
                           <component>
                              <section ID="ID_5af90d6c-fbd6-4e2c-aa4f-22587596dcd2">
                                 <id root="1bf06f23-ac5e-4fe0-8f9c-8714cd3b4836"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Disease-associated Maternal and/or Embryo-fetal Risk</content>
                                    </paragraph>
                                    <paragraph>COVID-19 in pregnancy is associated with adverse maternal and fetal outcomes, including preeclampsia, eclampsia, preterm birth, premature rupture of membranes, venous thromboembolic disease, and fetal death.</paragraph>
                                 </text>
                                 <effectiveTime value="20230531"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="Data">
                           <id root="a313e9d1-0c0a-440c-8a9b-b7295a52238e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="refdata">
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230531"/>
                           <component>
                              <section ID="ID_9abb23a2-9f04-49c4-9b8b-6ef9f9313a79">
                                 <id root="b4ed7a0a-76cb-44ca-a8a0-c4addc7a73fe"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20230531"/>
                                 <component>
                                    <section ID="ID_45808c8a-cd80-437a-8337-fe9901302579">
                                       <id root="383ddfcc-b3ad-43bf-8d6e-842035172ac1"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">
                                                <content styleCode="underline">Ritonavir</content>
                                             </content>
                                          </paragraph>
                                          <paragraph>Based on prospective reports to the antiretroviral pregnancy registry of live births following exposure to ritonavir-containing regimens (including over 3,500 live births exposed in the first-trimester and over 3,500 live births exposed in the second and third trimesters), there was no difference in the rate of overall birth defects for ritonavir compared with the background birth defect rate of 2.7% in the U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP). The prevalence of birth defects in live births was 2.4% [95% confidence interval (CI): 1.9%, 2.9%] following first-trimester exposure to ritonavir-containing regimens and 2.9% (95% CI: 2.4%, 3.5%) following second and third trimester exposure to ritonavir-containing regimens. While placental transfer of ritonavir and fetal ritonavir concentrations are generally low, detectable levels have been observed in cord blood samples and neonate hair.</paragraph>
                                       </text>
                                       <effectiveTime value="20230531"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_09f23319-9605-4788-996f-1efd9b0f58ff">
                                 <id root="2283d49e-44bf-4bbb-8e9e-80ab0f987226"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20230531"/>
                                 <component>
                                    <section ID="ID_af92f7c1-520f-414c-9fea-58ea0d833359">
                                       <id root="47fb426b-dee3-4d24-aa59-ab95a8d905f2"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">
                                                <content styleCode="underline">Nirmatrelvir</content>
                                             </content>
                                          </paragraph>
                                          <paragraph>Embryo-fetal developmental (EFD) toxicity studies were conducted in pregnant rats and rabbits administered oral nirmatrelvir doses of up to 1,000 mg/kg/day during organogenesis [on Gestation Days (GD) 6 through 17 in rats and GD 7 through 19 in rabbits]. No biologically significant developmental effects were observed in the rat EFD study. At the highest dose of 1,000 mg/kg/day, the systemic nirmatrelvir exposure (AUC<sub>24</sub>) in rats was approximately 9 times higher than clinical exposures at the approved human dose of PAXLOVID. In the rabbit EFD study, lower fetal body weights (9% decrease) were observed at 1,000 mg/kg/day in the absence of significant maternal toxicity findings. At 1,000 mg/kg/day, the systemic exposure (AUC<sub>24</sub>) in rabbits was approximately 11 times higher than clinical exposures at the approved human dose of PAXLOVID. No other significant developmental toxicities (malformations and embryo-fetal lethality) were observed up to the highest dose tested, 1,000 mg/kg/day. No developmental effects were observed in rabbits at 300 mg/kg/day resulting in systemic exposure (AUC<sub>24</sub>) approximately 3 times higher than clinical exposures at the approved human dose of PAXLOVID. A pre- and postnatal developmental (PPND) study in pregnant rats administered oral nirmatrelvir doses of up to 1,000 mg/kg/day from GD 6 through Lactation Day (LD) 20 showed no adverse findings. Although no difference in body weight was noted at birth when comparing offspring born to nirmatrelvir-treated versus control animals, a decrease in the body weight of offspring was observed on Postnatal Day (PND) 17 (8% decrease) and PND 21 (up to 7% decrease) in the absence of maternal toxicity. No significant differences in offspring body weight were observed from PND 28 to PND 56. The maternal systemic exposure (AUC<sub>24</sub>) at 1,000 mg/kg/day was approximately 9 times higher than clinical exposures at the approved human dose of PAXLOVID. No body weight changes in the offspring were noted at 300 mg/kg/day, where maternal systemic exposure (AUC<sub>24</sub>) was approximately 6 times higher than clinical exposures at the approved human dose of PAXLOVID.</paragraph>
                                       </text>
                                       <effectiveTime value="20230531"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section ID="ID_5cdb4899-2fdf-4c95-8d00-bb5516d5da71">
                                       <id root="6d45d5e1-6843-4649-b5c1-e4a1f42e86d2"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">
                                                <content styleCode="underline">Ritonavir</content>
                                             </content>
                                          </paragraph>
                                          <paragraph>Ritonavir was administered orally to pregnant rats (at 0, 15, 35, and 75 mg/kg/day) and rabbits (at 0, 25, 50, and 110 mg/kg/day) during organogenesis (on GD 6 through 17 in rats and GD 6 through 19 in rabbits). No evidence of teratogenicity due to ritonavir was observed in rats and rabbits at systemic exposures (AUC) 5 (rats) or 8 (rabbits) times higher than exposure at the approved human dose of PAXLOVID. Increased incidences of early resorptions, ossification delays, and developmental variations, as well as decreased fetal body weights were observed in rats in the presence of maternal toxicity, at systemic exposures (AUC) approximately 10 times higher than exposure at the approved human dose of PAXLOVID. In rabbits, resorptions, decreased litter size, and decreased fetal weights were observed at maternally toxic doses, at systemic exposures greater than 8 times higher than exposure at the approved human dose of PAXLOVID. In a PPND study in rats, administration of 0, 15, 35, and 60 mg/kg/day ritonavir from GD 6 through PND 20 resulted in no developmental toxicity, at ritonavir systemic exposures greater than 10 times the exposure at the approved human dose of PAXLOVID.</paragraph>
                                       </text>
                                       <effectiveTime value="20230531"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="81008a7a-ed67-4c50-a2e2-c22a54c758ec"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20241119"/>
                     <component>
                        <section ID="ID_f731a7f4-dfec-4444-816e-3b243037f6ae">
                           <id root="12d6c2e2-f0f3-4a3a-94ff-f62a51ef3e76"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Nirmatrelvir and ritonavir are present in human breast milk in small amounts (less than 2%). In a clinical lactation study in 8 lactating women, nirmatrelvir and ritonavir were estimated to be present in human milk at a mean weight-normalized infant daily dose of 0.16 mg/kg/day (1.8% of maternal weight-adjusted daily dose) and 0.006 mg/kg/day (0.2% of maternal weight-adjusted daily dose), respectively <content styleCode="italics">(see <linkHtml href="#reflacdata">Data</linkHtml>)</content>. </paragraph>
                              <paragraph>There are no available data on the effects of nirmatrelvir or ritonavir on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for PAXLOVID and any potential adverse effects on the breastfed infant from PAXLOVID or from the underlying maternal condition. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.</paragraph>
                           </text>
                           <effectiveTime value="20241119"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Data2">
                           <id root="c5414ceb-bbc9-487c-8949-833f9d239ac2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="reflacdata">
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                              <paragraph>In a clinical pharmacokinetics study, 8 healthy lactating women who were at least 12 weeks postpartum were administered 3 oral doses every 12 hours (steady state dosing) of 300 mg/100 mg nirmatrelvir/ritonavir. The mean daily amount of nirmatrelvir and ritonavir recovered in breast milk was 0.752 mg and 0.027 mg, respectively, representing 0.13% and 0.014% of the corresponding administered daily maternal doses (unadjusted for weight). The estimated daily infant dose (assuming average milk consumption of 150 mL/kg/day), was 0.16 mg/kg/day and 0.006 mg/kg/day, 1.8% and 0.2% of the maternal dose, respectively, for nirmatrelvir and ritonavir.</paragraph>
                           </text>
                           <effectiveTime value="20241119"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="cd96956f-3a3f-4baf-bc5e-7940962f8a8f"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <effectiveTime value="20230531"/>
                     <component>
                        <section ID="ID_d626f782-e5de-4347-a76f-c7e7dedf3bff">
                           <id root="e699c7cd-f633-4e62-b686-cd97dfd04249"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                              <paragraph>Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. Advise patients using combined hormonal contraceptives to use an effective alternative contraceptive method or an additional barrier method of contraception <content styleCode="italics">[see <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20230531"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="638c7b43-c2b9-4c90-9218-47cf1f4bc0ae"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The optimal dose of PAXLOVID has not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20230531"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="54e72814-5acb-4c73-a737-f39cceb9503d"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of PAXLOVID include subjects 65 years of age and older and their data contributes to the overall assessment of safety and efficacy <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml> and <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>. Of the total number of subjects in the integrated dataset consisting of EPIC-HR and EPIC-SR who were randomized to and received PAXLOVID (N=1,578), 165 (10%) were 65 years of age and older and 39 (2%) were 75 years of age and older. No overall differences in safety were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in safety between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</paragraph>
                     </text>
                     <effectiveTime value="20230531"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="d114ca2f-1399-4dfe-aaa6-a0a5bec9267f"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Renal impairment increases nirmatrelvir exposure, which may increase the risk of PAXLOVID adverse reactions. No dosage adjustment is recommended in patients with mild renal impairment (eGFR 60 to &lt;90 mL/min). Reduce the PAXLOVID dosage in patients with moderate renal impairment (eGFR 30 to &lt;60 mL/min). Reduce the PAXLOVID dose and dose frequency in patients with severe renal impairment (eGFR &lt;30 mL/min), including those requiring hemodialysis. On days when patients undergo hemodialysis, the PAXLOVID dose should be administered after hemodialysis <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>,<linkHtml href="#S6.1"> Adverse Reactions (6.1)</linkHtml>, and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. <content styleCode="italics">Prescriptions should specify the numeric dose of each active ingredient within PAXLOVID</content>. Providers should counsel patients about renal dosing instructions <content styleCode="italics">[see <linkHtml href="#S17">Patient Counseling Information (17)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="b4a21426-bb93-4239-9505-b47de5a2030d"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>No dosage adjustment of PAXLOVID is recommended for patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. No pharmacokinetic or safety data are available regarding the use of nirmatrelvir or ritonavir in subjects with severe (Child-Pugh Class C) hepatic impairment, therefore, PAXLOVID is not recommended for use in patients with severe (Child-Pugh Class C) hepatic impairment <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="f2aead03-c4eb-443e-897d-c6599723faf5"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Treatment of overdose with PAXLOVID should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with PAXLOVID.</paragraph>
               </text>
               <effectiveTime value="20230531"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="5c952b0d-ce6c-43af-a2b0-404ba1d192af"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets. Nirmatrelvir is a SARS-CoV-2 main protease (M<sup>pro</sup>) inhibitor, and ritonavir is an HIV-1 protease inhibitor and CYP3A inhibitor. </paragraph>
               </text>
               <effectiveTime value="20230531"/>
               <component>
                  <section ID="ID_4d189fe0-bdf2-494b-b2da-969aaf491834">
                     <id root="6488db7d-7266-4ee5-9344-fbd1e78c6537"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Nirmatrelvir</content>
                        </paragraph>
                        <paragraph>The chemical name of active ingredient of nirmatrelvir is (1<content styleCode="italics">R</content>,2<content styleCode="italics">S</content>,5<content styleCode="italics">S</content>)-<content styleCode="italics">N</content>-((1<content styleCode="italics">S</content>)-1-Cyano-2-((3<content styleCode="italics">S</content>)-2-oxopyrrolidin-3-yl)ethyl)-3-((2<content styleCode="italics">S</content>)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide]. It has a molecular formula of C<sub>23</sub>H<sub>32</sub>F<sub>3</sub>N<sub>5</sub>O<sub>4</sub> and a molecular weight of 499.54. Nirmatrelvir has the following structural formula:</paragraph>
                        <renderMultiMedia ID="id2787" referencedObject="e31b427f-6ac3-4eff-84f8-4d3db6ac4f43"/>
                        <paragraph>Nirmatrelvir is available as immediate-release, film-coated tablets. Each tablet contains 150 mg nirmatrelvir with the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, and sodium stearyl fumarate. The following are the ingredients in the film coating: hydroxy propyl methylcellulose, iron oxide red, polyethylene glycol, and titanium dioxide. </paragraph>
                     </text>
                     <effectiveTime value="20230531"/>
                     <component>
                        <observationMedia ID="e31b427f-6ac3-4eff-84f8-4d3db6ac4f43">
                           <text>Chemical Structure</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="paxlovid-01.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_239b37a8-ac78-418a-b153-6e2eefcc99fc">
                     <id root="4b0fb669-7f1a-4337-895f-7991ef3be0eb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Ritonavir</content>
                        </paragraph>
                        <paragraph>Ritonavir is chemically designated as 10-Hydroxy-2-methyl-5-(1-methylethyl)-1- [2-(1 methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12- tetraazatridecan-13-oic acid, 5-thiazolylmethyl ester, [5S-(5R*,8R*,10R*,11R*)]. Its molecular formula is C<sub>37</sub>H<sub>48</sub>N<sub>6</sub>O<sub>5</sub>S<sub>2</sub>, and its molecular weight is 720.95. Ritonavir has the following structural formula:</paragraph>
                        <renderMultiMedia ID="id2810" referencedObject="ID_219accc4-fe32-4f55-b7f4-eb77e4cb0a59"/>
                        <paragraph>Ritonavir is available as film-coated tablets. Each tablet contains 100 mg ritonavir with the following inactive ingredients: anhydrous dibasic calcium phosphate, colloidal silicon dioxide, copovidone, sodium stearyl fumarate, and sorbitan monolaurate. The film coating may include the following ingredients: colloidal anhydrous silica, colloidal silicon dioxide, hydroxypropyl cellulose, hypromellose, polyethylene glycol, polysorbate 80, talc, and titanium dioxide.</paragraph>
                     </text>
                     <effectiveTime value="20230531"/>
                     <component>
                        <observationMedia ID="ID_219accc4-fe32-4f55-b7f4-eb77e4cb0a59">
                           <text>Chemical Structure</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="paxlovid-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="f6c64efa-be28-419c-8a74-f6aba3b02aaf"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250212"/>
               <component>
                  <section ID="S12.1">
                     <id root="40dc28aa-4770-4acc-a382-bd6105ada9b9"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Nirmatrelvir is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral drug <content styleCode="italics">[see <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Ritonavir is an HIV-1 protease inhibitor but is not active against SARS-CoV-2 M<sup>pro</sup>. Ritonavir inhibits the CYP3A-mediated metabolism of nirmatrelvir, resulting in increased plasma concentrations of nirmatrelvir.</paragraph>
                     </text>
                     <effectiveTime value="20230531"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="8c957b65-2c90-4da4-90f0-7bbe8fce2dc1"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>At 3 times the steady state peak plasma concentration (C<sub>max</sub>) at the recommended dose, nirmatrelvir does not prolong the QTc interval to any clinically relevant extent.</paragraph>
                     </text>
                     <effectiveTime value="20230531"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="c0cdb2a1-b24d-43ac-bbd2-91668ae7de13"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The pharmacokinetics of nirmatrelvir/ritonavir were similar in healthy subjects and in subjects with mild-to-moderate COVID-19.</paragraph>
                        <paragraph>Nirmatrelvir AUC increased in a less than dose proportional manner over a single dose range from 250 mg to 750 mg (0.83 to 2.5 times the approved recommended dose) and multiple dose range from 75 mg to 500 mg (0.25 to 1.67 times the approved recommended dose), when administered in combination with 100 mg ritonavir. Nirmatrelvir steady state was achieved on Day 2 following administration of the approved recommended dosage and the mean accumulation ratio was approximately 2-fold. </paragraph>
                        <paragraph>The pharmacokinetic properties of nirmatrelvir/ritonavir are displayed in Table 3.</paragraph>
                        <table ID="_Reftable3" styleCode="Noautorules" width="75%">
                           <caption>Table 3:	Pharmacokinetic Properties of Nirmatrelvir and Ritonavir in Healthy Subjects</caption>
                           <col width="31%"/>
                           <col width="28%"/>
                           <col width="28%"/>
                           <thead>
                              <tr>
                                 <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <content styleCode="bold">Nirmatrelvir (When Given With Ritonavir)</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <content styleCode="bold">Ritonavir</content>
                                 </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">Abbreviations: CL/F=apparent clearance; hr=hour; L/hr=liters per hour; T<sub></sub>=terminal elimination half-life; T<sub>max</sub>=the time to reach C<sub>max</sub>; V<sub>z</sub>/F=apparent volume of distribution.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Absorption</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>T<sub>max</sub> (hr), median</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>3.00<footnote ID="_Reft3fa">Represents data after a single dose of 300 mg nirmatrelvir (2  150 mg tablet formulation) administered together with 100 mg ritonavir tablet in healthy subjects.</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>3.98<footnoteRef IDREF="_Reft3fa"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Food effect</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>Test/reference (fed/fasted) ratios of adjusted geometric means (90% CI) AUC<sub>inf</sub> and C<sub>max</sub> for nirmatrelvir were 119.67 (108.75, 131.68) and 161.01 (139.05, 186.44), respectively.<footnote ID="_Ref136006505">Following a single oral dose of nirmatrelvir 300 mg boosted ritonavir 100 mg at -12 hours, 0 hours and 12 hours, administered under fed (high fat and high calorie meal) or fasted conditions.</footnote>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Distribution</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>% bound to human plasma proteins</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>69%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>9899%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Blood-to-plasma ratio</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0.60</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0.14<footnote ID="_Ref189566366">Red blood cell to plasma ratio.</footnote>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>V<sub>z</sub>/F (L), mean</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>104.7<footnote ID="_Reft3fb">300 mg nirmatrelvir (oral suspension formulation) co-administered with 100 mg ritonavir (tablet formulation) twice daily for 3 days.</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>112.4<footnoteRef IDREF="_Reft3fb"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Elimination</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Major route of elimination</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Renal elimination</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Hepatic metabolism</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Half-life (T<sub></sub>) (hr), mean</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>6.05<footnoteRef IDREF="_Reft3fa"/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>6.15<footnoteRef IDREF="_Reft3fa"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Oral clearance (CL/F) (L/hr), mean</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>8.99<footnoteRef IDREF="_Reft3fb"/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>13.92<footnoteRef IDREF="_Reft3fb"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Metabolism</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Metabolic pathways</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Nirmatrelvir is a CYP3A substrate but when dosed with ritonavir, metabolic clearance is minimal.</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Major CYP3A, Minor CYP2D6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Excretion</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>% drug-related material in feces</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>35.3%<footnote ID="_Reft3fe">Determined by <sup>19</sup>F-NMR analysis following 300 mg nirmatrelvir oral suspension administered at 0 hr enhanced with 100 mg ritonavir at -12 hours, 0 hours, 12 hours, and 24 hours. </footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>86.4%<footnote ID="_Reft3ff">Determined by <sup>14</sup>C analysis following 600 mg <sup>14</sup>C-ritonavir oral solution (6 times the approved ritonavir dose).</footnote>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>% of dose excreted as total (unchanged drug) in feces</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>27.5%<footnoteRef IDREF="_Reft3fe"/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>33.8%<footnoteRef IDREF="_Reft3ff"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>% drug-related material in urine</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>49.6%<footnoteRef IDREF="_Reft3fe"/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>11.3%<footnoteRef IDREF="_Reft3ff"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>% of dose excreted as total (unchanged drug) in urine</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>55.0%<footnoteRef IDREF="_Reft3fe"/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>3.5%<footnoteRef IDREF="_Reft3ff"/>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The predicted Day 5 nirmatrelvir exposure parameters in adult subjects with mild-to-moderate COVID-19 who were treated with PAXLOVID in EPIC-HR are presented in Table 4.</paragraph>
                        <table ID="_Reftable4" styleCode="Noautorules" width="75%">
                           <caption>Table 4:	Predicted Day 5 Nirmatrelvir Exposure Parameters Following Administration of Nirmatrelvir/Ritonavir 300 mg/100 mg Twice Daily in Subjects with Mild-to-Moderate COVID-19</caption>
                           <col width="36%"/>
                           <col width="51%"/>
                           <thead>
                              <tr>
                                 <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <content styleCode="bold">Pharmacokinetic Parameter (units)</content>
                                    <footnote ID="_Ref136007324">Data presented as geometric mean (10<sup>th</sup> and 90<sup>th</sup> percentile).</footnote>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <content styleCode="bold">Nirmatrelvir</content>
                                    <footnote ID="_Ref136007365">Based on 1,017 subjects with their post hoc PK parameters.</footnote>
                                 </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="2" valign="top">Abbreviations: C<sub>max</sub>=predicted maximal concentration; C<sub>min</sub>=predicted minimal concentration (C<sub>trough</sub>).</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>C<sub>max</sub> (g/mL)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>3.29 (1.93, 5.40)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>AUC<sub>tau</sub> (g*hr/mL)<footnote ID="_Ref136007389">AUC<sub>tau</sub>=predicted area under the plasma concentration-time profile from time 0 to 12 hours for twice-daily dosing.</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>28.3 (12.5, 52.5)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>C<sub>min</sub> (g/mL)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>1.40 (0.48, 3.45)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250131"/>
                     <component>
                        <section ID="ID_d096f11c-6a63-4fef-acb6-d75932be6829">
                           <id root="5e4084e7-c1e0-4821-aa76-a8483bc4dbe6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Effect of Food</content>
                              </paragraph>
                              <paragraph>No clinically significant differences in the pharmacokinetics of nirmatrelvir were observed following administration of a high fat meal (800-1,000 calories; 50% fat) to healthy subjects.</paragraph>
                           </text>
                           <effectiveTime value="20250131"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_b6b71906-2114-4a09-8825-156cf46233eb">
                           <id root="d8b43e39-b047-43b0-a0ef-6b29ae2aa7e0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250131"/>
                           <component>
                              <section ID="ID_dd9e0613-08f1-42f9-9178-1b9b20059a95">
                                 <id root="7e53bf8f-43ca-4e03-afee-f3a5ae648f70"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>There were no clinically significant differences in the pharmacokinetics of nirmatrelvir based on age (18 to 86 years), sex, or race/ethnicity.</paragraph>
                                 </text>
                                 <effectiveTime value="20230531"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_db97ab32-8668-4694-a753-0103aeb07348">
                                 <id root="1106a25c-9b50-495c-bcac-f281ddf15c37"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pediatric Patients</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of nirmatrelvir/ritonavir in patients less than 18 years of age have not been established. </paragraph>
                                 </text>
                                 <effectiveTime value="20230531"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_df84046e-39c7-4583-8a2d-b4184d7bf4d4">
                                 <id root="9b0c6f22-9404-42ae-8596-d21d24676e8c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of nirmatrelvir in subjects with renal impairment following administration of a single oral dose of nirmatrelvir 100 mg (0.33 times the approved recommended dose) co-administered with ritonavir 100 mg were determined. Compared to healthy controls with no renal impairment, the C<sub>max</sub> and AUC of nirmatrelvir in subjects with mild renal impairment was 30% and 24% higher, in subjects with moderate renal impairment was 38% and 87% higher, and in subjects with severe renal impairment was 48% and 204% higher, respectively.</paragraph>
                                    <paragraph>The pharmacokinetics of nirmatrelvir in subjects with mild-to-moderate COVID-19 and severe renal impairment (eGFR&lt;30 mL/min) either requiring intermittent hemodialysis (n=12) or not requiring hemodialysis (n=2) were evaluated after administration of 300 mg/100 mg nirmatrelvir/ritonavir once on Day 1 followed by 150 mg/100 mg nirmatrelvir/ritonavir once daily on Days 2-5 for a total of 5 doses.</paragraph>
                                    <paragraph>The administration of 300 mg/100 mg nirmatrelvir/ritonavir once on Day 1 followed by 150 mg/100 mg nirmatrelvir/ritonavir once daily on Days 2-5 in subjects with severe renal impairment, either requiring intermittent hemodialysis or not requiring hemodialysis resulted in comparable exposures on Day 1 and at steady-state (AUC<sub>0-24 </sub>and Cmax) compared to those observed in subjects with normal renal function receiving 300 mg/100 mg nirmatrelvir/ritonavir twice daily for 5 days. During a 4-hour hemodialysis session, approximately 6.9% of nirmatrelvir dose was cleared through dialysis. Hemodialysis clearance was 1.83 L/h.</paragraph>
                                 </text>
                                 <effectiveTime value="20250131"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_d891b10c-382e-4e07-a672-46a099fd3ad0">
                                 <id root="dac3fd71-b297-45aa-a442-6dcf2c59d937"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of nirmatrelvir were similar in patients with moderate (Child-Pugh Class B) hepatic impairment compared to healthy subjects following administration of a single oral dose of nirmatrelvir 100 mg (0.33 times the approved recommended dose) co-administered with ritonavir 100 mg. The impact of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of nirmatrelvir or ritonavir has not been studied.</paragraph>
                                 </text>
                                 <effectiveTime value="20230531"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_fd6cbc90-1377-4af2-aaad-5e07f750d78a">
                           <id root="b5d6cb79-3179-44ab-a81b-92d103c6efa6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Drug Interaction Studies</content>
                              </paragraph>
                              <paragraph>Table 5 describes the effect of other drugs on the C<sub>max</sub> and AUC of nirmatrelvir.</paragraph>
                              <table ID="_Reftable8" styleCode="Noautorules" width="95%">
                                 <caption>Table 5:	The Effect of Other Drugs on the Pharmacokinetic Parameters of Nirmatrelvir</caption>
                                 <col width="18%"/>
                                 <col width="18%"/>
                                 <col width="18%"/>
                                 <col width="12%"/>
                                 <col width="17%"/>
                                 <col width="17%"/>
                                 <thead>
                                    <tr>
                                       <th align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                          <content styleCode="bold">Co-administered Drug</content>
                                       </th>
                                       <th align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                          <content styleCode="bold">Dose (Schedule)</content>
                                       </th>
                                       <th align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                          <content styleCode="bold">N</content>
                                       </th>
                                       <th align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                          <content styleCode="bold">Percent Ratio (in combination with co-administered drug/alone) of Nirmatrelvir Pharmacokinetic Parameters (90% CI); </content>
                                          <br/>
                                          <content styleCode="bold">No Effect=100</content>
                                       </th>
                                    </tr>
                                    <tr>
                                       <th align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                          <content styleCode="bold">Co-administered Drug</content>
                                       </th>
                                       <th align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                          <content styleCode="bold">Nirmatrelvir/ Ritonavir</content>
                                       </th>
                                       <th align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                          <content styleCode="bold">C<sub>max</sub>
                                          </content>
                                       </th>
                                       <th align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                          <content styleCode="bold">AUC</content>
                                          <footnote ID="_RefID0ELSCI">For carbamazepine, AUC=AUC<sub>inf</sub>; for itraconazole, AUC=AUC<sub>tau</sub>.</footnote>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="6" valign="top">Abbreviations: AUC=area under the plasma concentration-time curve; AUC<sub>inf</sub>=area under the plasma concentration-time profile from time zero extrapolated to infinite time; AUC<sub>tau</sub>=area under the plasma concentration-time profile from time zero to time tau (), the dosing interval. CI=confidence interval; C<sub>max</sub>=observed maximum plasma concentrations.</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Carbamazepine<footnote ID="_RefID0E6SCI">Carbamazepine titrated up to 300 mg twice daily on Day 8 through Day 15 (e.g., 100 mg twice daily on Day 1 through Day 3 and 200 mg twice daily on Day 4 through Day 7).</footnote>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>300 mg twice daily <br/>(16 doses)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>300 mg/100 mg once daily<br/>(2 doses)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>10</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>56.82<br/>(47.04, 68.62)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>44.50<br/>(33.77, 58.65)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>Itraconazole</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>200 mg once daily <br/>(8 doses)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>300 mg/100 mg twice daily<br/>(5 doses)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>11</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>118.57<br/>(112.50, 124.97)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>138.82<br/>(129.25, 149.11)</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Table 6 describes the effect of nirmatrelvir/ritonavir on the C<sub>max</sub> and AUC<sub>inf</sub> of other drugs.</paragraph>
                              <table ID="_Reftable9" styleCode="Noautorules" width="95%">
                                 <caption>Table 6:	Effect of Nirmatrelvir/Ritonavir on Pharmacokinetics of Other Drugs</caption>
                                 <col width="18%"/>
                                 <col width="18%"/>
                                 <col width="18%"/>
                                 <col width="12%"/>
                                 <col width="17%"/>
                                 <col width="17%"/>
                                 <thead>
                                    <tr>
                                       <th align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                          <content styleCode="bold">Co-administered Drug</content>
                                       </th>
                                       <th align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                          <content styleCode="bold">Dose (Schedule)</content>
                                       </th>
                                       <th align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                          <content styleCode="bold">N</content>
                                       </th>
                                       <th align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                          <content styleCode="bold">Percent Ratio of Test/Reference of Geometric Means (90% CI);</content>
                                          <br/>
                                          <content styleCode="bold">No Effect=100</content>
                                       </th>
                                    </tr>
                                    <tr>
                                       <th align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                          <content styleCode="bold">Co-administered Drug</content>
                                       </th>
                                       <th align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                          <content styleCode="bold">Nirmatrelvir/ Ritonavir</content>
                                       </th>
                                       <th align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                          <content styleCode="bold">C<sub>max</sub>
                                          </content>
                                       </th>
                                       <th align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                          <content styleCode="bold">AUC<sub>inf</sub>
                                          </content>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="6" valign="top">Abbreviations: AUC<sub>inf</sub>=area under the plasma concentration-time curve from time zero extrapolated to infinite time; CI=confidence interval; C<sub>max</sub>=observed maximum plasma concentrations; CYP3A4=cytochrome P450 3A4; OATP1B1=organic anion transporter polypeptide 1B1; P-gp=p-glycoprotein.</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Midazolam<footnote ID="_Ref182986703">For midazolam, Test=nirmatrelvir/ritonavir plus midazolam, Reference=Midazolam. Midazolam is an index substrate for CYP3A4. For dabigatran, Test=nirmatrelvir/ritonavir plus dabigatran, Reference=Dabigatran. Dabigatran is an index substrate for P-gp. For rosuvastatin, Test=nirmatrelvir/ritonavir plus rosuvastatin, Reference=Rosuvastatin. Rosuvastatin is an index substrate for OATP1B1.</footnote>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>2 mg <br/>(1 dose)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>300 mg/100 mg twice daily<br/>(9 doses)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>10</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>368.33<br/>(318.91, 425.41)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>1430.02<br/>(1204.54, 1697.71)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>Dabigatran<footnoteRef IDREF="_Ref182986703"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>75 mg <br/>(1 dose)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>300 mg/100 mg twice daily<br/>(4 doses)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>24</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>233.06<br/>(172.14, 315.54)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>194.47<br/>(155.29, 243.55)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>Rosuvastatin<footnoteRef IDREF="_Ref182986703"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>10 mg</paragraph>
                                          <paragraph>(1 dose)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>300mg/100mg twice daily<br/>(3doses)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>12</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>212.44</paragraph>
                                          <paragraph>(174.31, 258.90)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>131.18</paragraph>
                                          <paragraph>(115.89, 148.48)</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <content styleCode="italics">In Vitro Studies</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Cytochrome P450 (CYP) Enzymes: </content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>Nirmatrelvir is a reversible and time-dependent inhibitor of CYP3A, but not an inhibitor CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6. Nirmatrelvir is an inducer of CYP2B6, 2C8, 2C9, and 3A4, but there is minimal risk for pharmacokinetic interactions arising from induction of these CYP enzymes at the proposed therapeutic dose. </item>
                                 <item>
                                    <caption></caption>Ritonavir is a substrate of CYP2D6 and CYP3A. Ritonavir is an inducer of CYP1A2, CYP2C9, CYP2C19, CYP2B6, and CYP3A.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="italics">Transporter Systems:</content> Nirmatrelvir is an inhibitor of P-gp and OATP1B1. Nirmatrelvir is a substrate for P-gp, but not BCRP, MATE1, MATE2K, NTCP, OAT1, OAT2, OAT3, OCT1, OCT2, PEPT1, OATP1B1, OATP1B3, OATP2B1, or OATP4C1.</paragraph>
                           </text>
                           <effectiveTime value="20241119"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.4">
                     <id root="079882b6-1cbb-46b9-bdaf-586805d4386f"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Mechanism of Action</content>
                        </paragraph>
                        <paragraph>Nirmatrelvir is a peptidomimetic inhibitor of the SARS-CoV-2 main protease (M<sup>pro</sup>), also referred to as 3C-like protease (3CL<sup>pro</sup>) or nonstructural protein 5 (nsp5) protease. Inhibition of SARS-CoV-2 M<sup>pro</sup> renders it incapable of processing the viral polyproteins pp1a and pp1ab, preventing viral replication. Nirmatrelvir inhibited the activity of recombinant SARS-CoV-2 M<sup>pro</sup> in a biochemical assay with a K<sub>i</sub> value of 3.1 nM and an IC<sub>50</sub> value of 19.2 nM. Nirmatrelvir was found to bind directly to the SARS-CoV-2 M<sup>pro</sup> active site by X-ray crystallography.</paragraph>
                     </text>
                     <effectiveTime value="20250212"/>
                     <component>
                        <section ID="ID_3adf5fff-64fd-4484-828e-be51068d9eae">
                           <id root="edee0842-2f98-45d7-8385-a1b20ae61e12"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Antiviral Activity</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Cell Culture Antiviral Activity</content>
                              </paragraph>
                              <paragraph>Nirmatrelvir exhibited antiviral activity against SARS-CoV-2 (USA-WA1/2020 isolate) infection of differentiated normal human bronchial epithelial (dNHBE) cells with EC<sub>50</sub> and EC<sub>90</sub> values of 62 nM (31 ng/mL) and 181 nM (90 ng/mL), respectively, after 3 days of drug exposure.</paragraph>
                              <paragraph>The antiviral activity of nirmatrelvir against the Omicron sub-variants BA.2, BA.2.12.1, BA.4, BA.4.6, BA.5, BF.7, BQ.1, BQ.1.11, XBB.1.5, EG.5, and JN.1 was assessed in Vero E6-TMPRSS2 cells in the presence of a P-gp inhibitor. Nirmatrelvir had a median EC<sub>50</sub> value of 88 nM (range: 39-146 nM) against the Omicron sub-variants, reflecting EC<sub>50</sub> value fold changes 1.8 relative to the USA-WA1/2020 isolate.</paragraph>
                              <paragraph>In addition, the antiviral activity of nirmatrelvir against the SARS-CoV-2 Alpha, Beta, Gamma, Delta, Lambda, Mu, and Omicron BA.1 variants was assessed in Vero E6 P-gp knockout cells. Nirmatrelvir had a median EC<sub>50</sub> value of 25 nM (range: 16-141 nM). The Beta variant was the least susceptible variant tested, with an EC<sub>50</sub> value fold change of 3.7 relative to USA-WA1/2020. The other variants had EC<sub>50</sub> value fold changes 1.1 relative to USA-WA1/2020.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Clinical Antiviral Activity</content>
                              </paragraph>
                              <paragraph>In clinical trial EPIC-HR, which enrolled subjects who were primarily infected with the SARS-CoV-2 Delta variant, PAXLOVID treatment was associated with a 0.83 log<sub>10</sub> copies/mL greater median decline in viral RNA shedding levels in nasopharyngeal samples through Day 5 (mITT1 analysis set, all treated subjects with onset of symptoms 5 days who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment); similar results were observed in the mITT2 analysis set (all treated subjects with onset of symptoms 5 days). In the EPIC-SR trial, which included subjects who were infected with SARS-CoV-2 Delta (79%) or Omicron (19%) variants, PAXLOVID treatment was associated with a 1.05 log<sub>10</sub> copies/mL greater median decline in viral RNA shedding levels in nasopharyngeal samples through Day 5, with similar declines observed in subjects infected with Delta or Omicron variants. The degree of reduction in viral RNA levels relative to placebo following 5 days of PAXLOVID treatment was similar between unvaccinated high-risk subjects in EPIC-HR and vaccinated high-risk subjects in EPIC-SR.</paragraph>
                           </text>
                           <effectiveTime value="20250212"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_506746c7-ddb2-479c-856b-8829d427d7e3">
                           <id root="72564fb3-954c-4adc-8cd2-b50a19986505"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Antiviral Resistance</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">In Cell Culture and Biochemical Assays</content>
                              </paragraph>
                              <paragraph>SARS-CoV-2 M<sup>pro</sup> residues potentially associated with nirmatrelvir resistance have been identified using a variety of methods, including SARS-CoV-2 resistance selection, testing of recombinant SARS-CoV-2 viruses with M<sup>pro</sup> substitutions, and biochemical assays with recombinant SARS-CoV-2 M<sup>pro</sup> containing amino acid substitutions. Table 7 indicates M<sup>pro</sup> substitutions and combinations of M<sup>pro</sup> substitutions that have been observed in SARS-CoV-2 under nirmatrelvir selective pressure in cell culture. Individual M<sup>pro</sup> substitutions are listed regardless of whether they occurred alone or in combination with other M<sup>pro</sup> substitutions. Note that the M<sup>pro</sup> S301P and T304I substitutions overlap the P6 and P3 positions of the nsp5/nsp6 cleavage site located at the C-terminus of M<sup>pro</sup>. Substitutions at other M<sup>pro</sup> cleavage sites have not been associated with nirmatrelvir resistance in cell culture. The clinical significance of these substitutions is unknown.</paragraph>
                              <table width="100%">
                                 <col width="29%"/>
                                 <col width="71%"/>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="2" valign="top">Abbreviation: ND=no data.</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td colspan="2" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Table 7: SARS-CoV-2 Mpro Amino Acid Substitutions Selected by Nirmatrelvir in Cell Culture</content>
                                             <footnote ID="_Ref189568333">EC50 value fold change ranges are shown in instances where multiple data points have been reported.</footnote>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>Single Substitutions</paragraph>
                                          <paragraph>(EC<sub>50</sub> value fold change in cell culture)</paragraph>
                                       </td>
                                       <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>T21I (1.1-4.8), S46F (ND), L50F (1.2-4.2), P108S (ND), T135I (ND), F140L (4.1), S144A (2.2-5.3), C160F (2.1), E166A (3.3), E166V (25288), L167F (1.9-2.5), T169I (ND), H172Y (15), A173V (0.9-2.3), V186A (ND), R188G (ND), A191V (0.7-1.5), A193P (ND), P252L (5.9), S301P (ND), and T304I (1.4-5.5).</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>2 Substitutions</paragraph>
                                          <paragraph>(EC<sub>50</sub> value fold change in cell culture)</paragraph>
                                       </td>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>T21I+S144A (9.4), T21I+E166V (83-250), T21I+A173V (3.1-8.9), T21I+T304I (3.0-7.9), L50F+E166V (34-175), L50F+T304I (5.9), T135I+T304I (3.8), F140L+A173V (10-17), H172Y+P252L (ND), A173V+T304I (5.8-20), T21I+L50F+A193P+S301P (29), T21I+S144A+T304I (11-28), T21I+C160F+A173V+V186A+T304I (28-29), T21I+A173V+T304I (15-16), and L50F+F140L+L167F+T304I (43-55).</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Table 8 indicates Mpro substitutions and combinations of Mpro substitutions that have been found to reduce nirmatrelvir activity 3-fold (based on IC50 or Ki values) in biochemical assays using recombinant SARS-CoV-2 Mpro. Note that these Mpro substitutions were laboratory engineered and most were not observed in PAXLOVID-treated subjects in clinical trials. In addition, according to public sequence databases, most of these substitutions have not been observed in clinical isolates or have been observed but with global cumulative frequencies 0.002%. Thus, the clinical relevance of these substitutions is unclear. The following Mpro substitutions and combinations of Mpro substitutions emerged in cell culture in the presence of nirmatrelvir but conferred &lt;3-fold reduced nirmatrelvir activity in biochemical assays: T21I, S46F, L50F, P108S, T135I, C160F, T169I, V186A, A191V, A193P, P252L, S301P, T304I, T21I+T304I, and L50F+T304I.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Table 8:	SARS-CoV-2 Mpro Amino Acid Substitutions That Reduce Nirmatrelvir Activity 3-Fold in Biochemical Assays</content>
                              </paragraph>
                              <table styleCode="Noautorules" width="100%">
                                 <col width="37%"/>
                                 <col width="63%"/>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>Single Substitutions</paragraph>
                                          <paragraph>(IC50/Ki value fold change in biochemical assay)</paragraph>
                                       </td>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>Y54A/C (3.0-25), F140A/L/S (1.2-230), G143S (3.6-148), S144A/F/G/M/W/Y (1.2-76), S144D/E/H/Q/T/V (81-480), S144K/L/P/R (1,165-&gt;5,319), H164N (1.9-6.7), M165D/F/G/T (5.7-51), M165H/K/P/R/W (&gt;384), M165Y (3,838), E166A/G/K/L/Q (4.5-77), E166D/H/I/N/V/Y (143-708), E166R/V (&gt;1,538-7,700), L167F (1.4-4.5), P168del (4.5-9.3), H172D/F/G/K/Q/Y (10-91), H172A/C/E/M/N/R/V/Y (114-858), H172I/L/S/T (1,172-6,740), A173S/V (4.1-52), R188G (38), Q189E/K (1.6-16), Q192A/C/D/E/F/G/H/I/K/L/P/R/S/T/V/W (5.0-61), Q192Y (&gt;384), A260V (0.6-3.3), and V297A (3.0).</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>2 Substitutions</paragraph>
                                          <paragraph>(IC50/Ki value fold change in biochemical assay)</paragraph>
                                       </td>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>T21I+S144A (20), T21I+E166V (120-11,000), T21I+A173V (15), L50F+E166V (100-4,500), T135I+T304I (5.1), F140L+A173V (95), S144A+T304I (28), E166V+L232R (5,700), P168del+A173V (170-536), H172Y+P252L (180), A173V+T304I (28), T21I+S144A+T304I (51), T21I+A173V+T304I (55), L50F+E166A+L167F (52-180), T21I+L50F+A193P+S301P (7.3), L50F+F140L+L167F+T304I (190), and T21I+C160F+A173V+V186A+T304I (28).</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <content styleCode="italics">In Clinical Trials</content>
                              </paragraph>
                              <paragraph>Treatment-emergent substitutions were evaluated among subjects in clinical trials EPIC-HR/SR with sequence data available at both baseline and post-baseline visits (n=907 PAXLOVID-treated subjects, n=946 placebo-treated subjects). SARS-CoV-2 M<sup>pro</sup> amino acid changes were classified as PAXLOVID treatment-emergent substitutions if they occurred at the same amino acid position in 3 or more PAXLOVID-treated subjects and were 2.5-fold more common in PAXLOVID-treated subjects than placebo-treated subjects. The following PAXLOVID treatment-emergent M<sup>pro</sup> substitutions were observed: T98I/R/del(n=4), E166V (n=3), and W207L/R/del (n=4). In biochemical assays, the T98I and W207L/R substitutions did not affect nirmatrelvir activity (Ki value fold changes were 0.3 and 0.7/0.3, respectively), whereas the E166V substitution (which occurs at a M<sup>pro</sup>-nirmatrelvir contact residue) reduced nirmatrelvir activity 187-7,700-fold. Within the M<sup>pro</sup> cleavage sites, the following PAXLOVID treatment-emergent substitutions were observed: A5328S/V(n=7) and S6799A/P/Y (n=4). These cleavage site substitutions were not associated with the co-occurrence of any specific M<sup>pro</sup> substitutions. In a cell culture replicon assay, the A5328S/V and S6799A substitutions did not affect nirmatrelvir activity (EC50 value fold changes were 0.3/0.2 and 0.7, respectively).</paragraph>
                              <paragraph>None of the treatment-emergent substitutions listed above in M<sup>pro</sup> or M<sup>pro</sup> cleavage sites occurred in PAXLOVID-treated subjects who experienced hospitalization. Thus, the clinical significance of these substitutions is unknown.</paragraph>
                           </text>
                           <effectiveTime value="20250212"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_add24866-0da9-4b68-9514-1bd04d6a82ff">
                           <id root="17274296-2363-4e99-9ce3-ae06e16b3337"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Viral RNA Rebound and Treatment-Emergent Substitutions</content>
                              </paragraph>
                              <paragraph>EPIC-HR and EPIC-SR were not designed to evaluate COVID-19 rebound; exploratory analyses were conducted to assess the relationship between PAXLOVID use and rebound in viral RNA shedding levels.</paragraph>
                              <paragraph>Post-treatment increases in SARS-CoV-2 RNA shedding levels in nasopharyngeal samples were observed on Day 10 and/or Day 14 in a subset of PAXLOVID and placebo recipients in EPIC-HR and EPIC-SR, irrespective of COVID-19 symptoms. The frequency of detection of post-treatment viral RNA rebound varied according to analysis parameters, but was generally similar among PAXLOVID and placebo recipients. A similar or smaller percentage of placebo recipients compared to PAXLOVID recipients had nasopharyngeal viral RNA results &lt; lower limit of quantitation (LLOQ) at all study timepoints in both the treatment and post-treatment periods. </paragraph>
                              <paragraph>In EPIC-HR, of 59 PAXLOVID-treated subjects identified with post-treatment viral RNA rebound and with available viral sequence data, treatment-emergent substitutions in M<sup>pro</sup> potentially reducing nirmatrelvir activity were detected in 2 (3%) subjects, including E166V in 1 subject and T304I in 1 subject. Both subjects had viral RNA shedding levels &lt;LLOQ by Day 14.</paragraph>
                              <paragraph>Post-treatment viral RNA rebound was not associated with the primary clinical outcome of COVID-19 related hospitalization or death from any cause through Day 28 following the single 5-day course of PAXLOVID treatment. The clinical relevance of post-treatment increases in viral RNA following PAXLOVID or placebo treatment is unknown. </paragraph>
                           </text>
                           <effectiveTime value="20240916"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_40b9ee56-387a-4789-b264-43be448871a7">
                           <id root="1675cf10-49aa-4240-b05a-83b6bdb1d14e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cross-Resistance</content>
                              </paragraph>
                              <paragraph>Cross-resistance is not expected between nirmatrelvir and remdesivir or any other anti-SARS-CoV-2 agents with different mechanisms of action (i.e., agents that are not M<sup>pro</sup> inhibitors).</paragraph>
                           </text>
                           <effectiveTime value="20230531"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="ae687b31-8199-4375-bf76-45fa3651a0c0"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20230531"/>
               <component>
                  <section ID="S13.1">
                     <id root="67a541a9-ef48-4da9-8932-672fbaafa4c2"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20230531"/>
                     <component>
                        <section ID="ID_299acb30-376e-4102-b23f-32c43d562fd3">
                           <id root="65a3a000-0d47-4b65-9beb-06afa6954fcd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Nirmatrelvir</content>
                              </paragraph>
                              <paragraph>Carcinogenicity studies have not been conducted with nirmatrelvir.</paragraph>
                              <paragraph>Nirmatrelvir was negative for mutagenic or clastogenic activity in a battery of <content styleCode="italics">in vitro</content> and <content styleCode="italics">in vivo</content> assays including the Ames bacterial reverse mutation assay using <content styleCode="italics">S. typhimurium</content> and <content styleCode="italics">E. coli</content>, the <content styleCode="italics">in vitro</content> micronucleus assay using human lymphoblastoid TK6 cells, and the <content styleCode="italics">in vivo</content> rat micronucleus assays.</paragraph>
                              <paragraph>In a fertility and early embryonic development study, nirmatrelvir was administered orally to male and female rats at doses of 60, 200, or 1,000 mg/kg/day once daily beginning 14 days prior to mating, throughout the mating phase, and continued through GD 6 for females and for a total of 32 doses for males. There were no effects on fertility, reproductive performance, or early embryonic development at doses up to 1,000 mg/kg/day, resulting in systemic exposure (AUC<sub>24</sub>) approximately 5 times higher than exposure at the approved human dose of PAXLOVID.</paragraph>
                           </text>
                           <effectiveTime value="20230531"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_ad6e3091-b64f-47db-bf73-750076162ed6">
                           <id root="ac1122ef-aeae-46c5-b32c-6c8a6b4314f8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Ritonavir</content>
                              </paragraph>
                              <paragraph>Carcinogenicity studies in mice and rats have been conducted on ritonavir. In male mice, at levels of 50, 100, or 200 mg/kg/day, there was a dose dependent increase in the incidence of both adenomas and combined adenomas and carcinomas in the liver. Based on AUC measurements, the exposure at the high dose was approximately 25 times higher than the exposure in humans at the approved human dose of PAXLOVID. No carcinogenic effects were observed in females at up to the highest dose tested, resulting in systemic exposure (AUC<sub>24</sub>) approximately 25 times higher than the exposure in humans at the approved human dose of PAXLOVID. In rats dosed at levels of 7, 15, or 30 mg/kg/day, there were no carcinogenic effects. In this study, the exposure at the high dose was approximately 5 times higher than the exposure in humans at the approved human dose of PAXLOVID.</paragraph>
                              <paragraph>Ritonavir was found to be negative for mutagenic or clastogenic activity in a battery of <content styleCode="italics">in vitro</content> and <content styleCode="italics">in vivo</content> assays including the Ames bacterial reverse mutation assay using <content styleCode="italics">S. typhimurium</content> and <content styleCode="italics">E. coli</content>, the mouse lymphoma assay, the mouse micronucleus test and chromosomal aberration assays in human lymphocytes.</paragraph>
                              <paragraph>Ritonavir produced no effects on fertility in rats at drug exposures approximately 18 (male) and 27 (female) times higher than the exposure in humans at the approved human dose of PAXLOVID.</paragraph>
                           </text>
                           <effectiveTime value="20230531"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="e2f85339-6015-41d4-bf7e-0dbaba08f42e"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250131"/>
               <component>
                  <section ID="S14.1">
                     <id root="1974ecf0-ee34-44f1-93a7-6cba00c384e2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1	Efficacy in Subjects at High Risk of Progression to Severe COVID-19 (EPIC-HR)</title>
                     <text>
                        <paragraph>EPIC-HR (NCT04960202) was a Phase 2/3, randomized, double-blind, placebo-controlled trial in non-hospitalized symptomatic adult subjects with a laboratory confirmed diagnosis of SARS-CoV-2 infection. Eligible subjects were 18 years of age and older with at least 1 of the following risk factors for progression to severe disease: diabetes, overweight (BMI &gt;25), chronic lung disease (including asthma), chronic kidney disease, current smoker, immunosuppressive disease or immunosuppressive treatment, cardiovascular disease, hypertension, sickle cell disease, neurodevelopmental disorders, active cancer, medically-related technological dependence, or were 60 years of age and older regardless of comorbidities. Subjects with COVID-19 symptom onset of 5 days were included in the study. Subjects were randomized (1:1) to receive PAXLOVID (nirmatrelvir/ritonavir 300 mg/100 mg) or placebo orally every 12 hours for 5 days. The trial excluded individuals with a history of prior COVID-19 infection or vaccination and excluded individuals taking any medications with clinically significant drug interactions with PAXLOVID. The primary efficacy endpoint was the proportion of subjects with COVID-19 related hospitalization or death from any cause through Day 28. The analysis was conducted in the modified intent-to-treat (mITT) analysis set [all treated subjects with onset of symptoms 3 days who at baseline did not receive nor were expected to receive COVID-19 therapeutic monoclonal antibody (mAb) treatment], the mITT1 analysis set (all treated subjects with onset of symptoms 5 days who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment), and the mITT2 analysis set (all treated subjects with onset of symptoms 5 days).</paragraph>
                        <paragraph>A total of 2,113 subjects were randomized to receive either PAXLOVID or placebo. At baseline, mean age was 45 years; 51% were male; 71% were White, 15% were Asian, 9% were American Indian or Alaska Native, 4% were Black or African American, and 1% was missing or unknown; 41% were Hispanic or Latino; 67% of subjects had onset of symptoms 3 days before initiation of study treatment; 49% of subjects were serological negative at baseline; the mean (SD) baseline viral RNA in nasopharyngeal samples was 4.71 log<sub>10</sub> copies/mL (2.89); 27% of subjects had a baseline viral RNA of 10^7 (log<sub>10</sub> copies/mL); 6% of subjects either received or were expected to receive COVID-19 therapeutic monoclonal antibody treatment at the time of randomization and were excluded from the mITT and mITT1 analyses.</paragraph>
                        <paragraph>The baseline demographic and disease characteristics were balanced between the PAXLOVID and placebo groups.</paragraph>
                        <paragraph>The proportions of subjects who discontinued treatment due to an adverse event were 2.0% in the PAXLOVID group and 4.2% in the placebo group.</paragraph>
                        <paragraph>Table 9 provides results of the primary endpoint in mITT1 analysis population. For the primary endpoint, the relative risk reduction in the mITT1 analysis population for PAXLOVID compared to placebo was 86% (95% CI: 72%, 93%).</paragraph>
                        <table ID="_Reftable10" styleCode="Noautorules" width="75%">
                           <caption>Table 9:	COVID-19 Related Hospitalization or Death from Any Cause Through Day 28 in Non-Hospitalized Adults with COVID-19 (mITT1 Analysis Set): EPIC-HR</caption>
                           <col width="42%"/>
                           <col width="23%"/>
                           <col width="22%"/>
                           <thead>
                              <tr>
                                 <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <content styleCode="bold">PAXLOVID</content>
                                    <br/>
                                    <content styleCode="bold">(N=977)</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">(N=989)</content>
                                 </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">Abbreviations: CI=confidence interval; COVID-19=coronavirus disease 2019; mAb=monoclonal antibody; mITT1=modified intent-to-treat 1 (all treated subjects with onset of symptoms 5 days who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment). <br/>The determination of primary efficacy was based on a planned interim analysis of 754 subjects in mITT population. The estimated risk reduction was -6.5% with a 95% CI of (-9.3%, -3.7%) and 2-sided p-value &lt;0.0001.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>COVID-19 Related Hospitalization or Death from Any Cause Through Day 28 </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>n (%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>9 (0.9%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>64 (6.5%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Reduction Relative to Placebo<footnote ID="_RefID0EPEDI">The estimated cumulative proportion of subjects hospitalized or death by Day 28 was calculated for each treatment group using the Kaplan-Meier method, where subjects without hospitalization and death status through Day 28 were censored at the time of study discontinuation.</footnote> (95% CI), %</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>-5.6 (-7.3, -4.0)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>COVID-19 Related Hospitalization Through Day 28, %</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>9 (0.9%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>63 (6.4%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>All-cause Mortality Through Day 28<footnote ID="_Ref136009300">For the secondary endpoint of all-cause mortality through Week 24, there were 0 and 15 (1%) events in the PAXLOVID arm and placebo arm, respectively.</footnote>, %</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>12 (1.2%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Consistent results were observed in the mITT and mITT2 analysis populations.</paragraph>
                        <paragraph>Similar trends have been observed across subgroups of subjects <content styleCode="italics">(see <linkHtml href="#Figure1">Figure 1</linkHtml>)</content>.</paragraph>
                        <paragraph ID="Figure1">
                           <content styleCode="bold">Figure 1:	Subgroup Analysis of Adults with COVID-19 Dosed within 5 Days of Symptom Onset with COVID-19 Related Hospitalization or Death from Any Cause Through Day 28: EPIC-HR</content>
                        </paragraph>
                        <table styleCode="Noautorules" width="100%">
                           <col width="100%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="1" valign="top">Abbreviations: BMI=body mass index; COVID-19=coronavirus disease 2019; mAb=monoclonal antibody; mITT=modified intent-to-treat; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.<br/>N=number of subjects in the category of the analysis set.<br/>All categories are based on mITT1 population except for COVID-19 mAb treatment which is based on mITT2 population.<br/>Seropositivity was defined if results were positive in either Elecsys anti-SARS-CoV-2 S or Elecsys anti-SARS-CoV-2 (N) assay.<br/>The difference of the proportions in the 2 treatment groups and its 95% confidence interval based on normal approximation of the data are presented.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" valign="middle">
                                    <renderMultiMedia ID="id-1961259962" referencedObject="f5f006d7-c353-4344-a7e6-9973a2993a14"/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Among subjects who were SARS-CoV-2 seropositive at baseline, 1/490 (0.2%) PAXLOVID recipients versus 8/479 (1.7%) placebo recipients met the primary endpoint of COVID-19 related hospitalization or death from any cause through Day 28 [reduction relative to placebo -1.47% (-2.70%, -0.25%)].</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                     <component>
                        <observationMedia ID="f5f006d7-c353-4344-a7e6-9973a2993a14">
                           <text>Figure 1</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="paxlovid-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="e188b7ef-27e7-4354-88f4-70e86990b99d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2	Trial in Unvaccinated Subjects Without a Risk Factor for Progression to Severe COVID-19 or Subjects Fully Vaccinated Against COVID-19 With at Least One Factor for Progression to Severe COVID-19 (EPIC-SR)</title>
                     <text>
                        <paragraph>PAXLOVID is not indicated for the treatment of COVID-19 in patients without a risk factor for progression to severe COVID-19.</paragraph>
                        <paragraph>EPIC-SR (NCT05011513) was a Phase 2/3, randomized, double-blind, placebo-controlled trial in non-hospitalized symptomatic adult subjects with a laboratory confirmed diagnosis of SARS-CoV-2 infection. Eligible subjects were 18 years of age or older with COVID-19 symptom onset of 5 days who were at standard risk for progression to severe disease. The trial included previously unvaccinated subjects with no risk factors for progression to severe disease or subjects fully vaccinated against COVID-19 (i.e., completed a primary vaccination series) with at least 1 of the risk factors for progression to severe disease as defined in EPIC-HR. Through the December 19, 2021, data cutoff, a total of 1,075 subjects were randomized (1:1) to receive PAXLOVID or placebo orally every 12 hours for 5 days; of these, 59% were fully vaccinated high-risk subjects. </paragraph>
                        <paragraph>The primary endpoint in this trial, the difference in time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 among PAXLOVID versus placebo recipients, was not met. </paragraph>
                        <paragraph>In an exploratory analysis of the subgroup of fully vaccinated subjects with at least 1 risk factor for progression to severe disease, a non-statistically significant numerical reduction relative to placebo for the secondary endpoint of COVID-19 related hospitalization or death from any cause through Day 28 was observed.</paragraph>
                     </text>
                     <effectiveTime value="20230531"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.3">
                     <id root="96af8194-4851-4090-93ba-a59f42451f4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3	Post-Exposure Prophylaxis Trial</title>
                     <text>
                        <paragraph>PAXLOVID is not indicated for the post-exposure prophylaxis of COVID-19.</paragraph>
                        <paragraph>In a double-blind, double-dummy, placebo-controlled trial, the efficacy of PAXLOVID when administered for 5 or 10 days as post-exposure prophylaxis of COVID-19 was evaluated. Eligible subjects were asymptomatic adults 18 years of age and older who were SARS-CoV-2 negative at baseline and who lived in the same household with symptomatic individuals with a recent diagnosis of SARS-CoV-2. A total of 2,736 subjects were randomized (1:1:1) to receive PAXLOVID orally every 12 hours for 5 days, PAXLOVID orally every 12 hours for 10 days, or placebo. </paragraph>
                        <paragraph>The primary endpoint for this trial was not met. The primary endpoint was the risk reduction between the 5-day and 10-day PAXLOVID regimens versus placebo in the proportion of subjects who developed RT-PCR or RAT-confirmed symptomatic SARS-CoV-2 infection through Day 14 who had a negative SARS-CoV-2 RT-PCR result at baseline. The proportion of subjects who had events through Day 14 was 2.6% for the 5-day PAXLOVID regimen, 2.4% for the 10-day PAXLOVID regimen, and 3.9% for placebo. There was not a statistically significant risk reduction versus placebo for either the 5-day or 10-day PAXLOVID regimen.</paragraph>
                     </text>
                     <effectiveTime value="20230531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="f6a48afe-084c-46b6-b9b1-d531c76835a4"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250212"/>
               <component>
                  <section ID="ID_4ae65012-ea1f-4ae9-9e02-c41f9e259dbb">
                     <id root="ed53a8bd-a7ba-458a-bc73-943dc8b59b13"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">How Supplied</content>
                        </paragraph>
                        <paragraph>PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets. It is supplied in three different Dose Packs.</paragraph>
                        <paragraph>Nirmatrelvir tablets and ritonavir tablets are supplied in separate blister cavities within the same child-resistant blister card.</paragraph>
                        <table styleCode="Noautorules" width="95%">
                           <col width="26%"/>
                           <col width="25%"/>
                           <col width="23%"/>
                           <col width="25%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Dose Pack</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Content</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">NDC</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Description</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="6" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">300 mg nirmatrelvir; 100 mg ritonavir</content>
                                    </paragraph>
                                 </td>
                                 <td rowspan="3" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Each Carton Contains:</content>
                                       <br/>
                                       <br/>30 tablets divided in<br/>10 blister cards</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0069-5045-30</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side.<br/>
                                       <br/>Ritonavir tablets: White to off-white, capsule-shaped, film-coated tablets debossed with "H" on one side and R9 on the other side.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <br/>Or<br/>
                                       <br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0069-5321-30</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side.<br/>
                                       <br/>Ritonavir tablets: White film-coated ovaloid tablets debossed with "NK" on one side.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="3" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Each Blister Card Contains:</content>
                                       <br/>
                                       <br/>2 nirmatrelvir tablets<br/>(150 mg each) and<br/>1 ritonavir tablet<br/>(100 mg)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0069-5045-06</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side.<br/>
                                       <br/>Ritonavir tablets: White to off-white, capsule-shaped, film-coated tablets debossed with "H" on one side and R9 on the other side.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <br/>Or<br/>
                                       <br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0069-5321-03</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side.<br/>
                                       <br/>Ritonavir tablets: White film-coated ovaloid tablets debossed with "NK" on one side.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">150 mg nirmatrelvir; 100 mg ritonavir</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Each Carton Contains:</content>
                                       <br/>
                                       <br/>20 tablets divided in<br/>10 blister cards</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0069-5317-20</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side.<br/>
                                       <br/>Ritonavir tablets: White film-coated ovaloid tablets debossed with NK on one side.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Each Blister Card Contains:</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">
                                          <br/>
                                       </content>1 nirmatrelvir tablet <br/>(150 mg) and <br/>1 ritonavir tablet <br/>(100 mg)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0069-5317-02</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side.<br/>
                                       <br/>Ritonavir tablets: White film-coated ovaloid tablets debossed with NK on one side.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">300 mg nirmatrelvir; <br/>100 mg ritonavir (Day 1)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">150 mg nirmatrelvir;<br/>100 mg ritonavir (Days 2-5)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Each Carton Contains:</content>
                                       <br/>
                                       <br/>11 tablets in <br/>1 blister card</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0069-0521-11</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side.<br/>
                                       <br/>Ritonavir tablets: White film-coated ovaloid tablets debossed with NK on one side.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Each Blister Card Contains:</content>
                                    </paragraph>
                                    <paragraph>6 nirmatrelvir tablets <br/>(150 mg) and <br/>5 ritonavir tablets <br/>(100 mg)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>0069-0521-11</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Nirmatrelvir tablets: Oval, pink immediate-release, film-coated tablets debossed with "PFE" on one side and "3CL" on the other side.<br/>
                                       <br/>Ritonavir tablets: White film-coated ovaloid tablets debossed with NK on one side.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250212"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_27667d44-0edb-46d6-b6f8-83bf907af028">
                     <id root="dac4be00-ddf5-4c10-ace8-a41b6c1eb853"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage and Handling</content>
                        </paragraph>
                        <paragraph>Store at USP controlled room temperature 20C to 25C (68F to 77F); excursions permitted between 15C to 30C (59F to 86F).</paragraph>
                     </text>
                     <effectiveTime value="20230531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="e56986bd-d2fa-4e71-81dc-8016ebee0e80"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
               </text>
               <effectiveTime value="20250131"/>
               <component>
                  <section ID="ID_8bb4f311-c9a3-4991-a764-bf8b9e3911c8">
                     <id root="fa311654-2f25-42e1-9ee1-ac013c227da2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions</content>
                        </paragraph>
                        <paragraph>Inform patients that PAXLOVID may interact with certain drugs and is contraindicated for use with certain drugs; therefore, advise patients to report to their healthcare provider the use of any prescription, non-prescription medication, or herbal products <content styleCode="italics">[see <linkHtml href="#ID_B0934FDD-6987-40BD-B71F-F0E00DD7AD3F">Boxed Warning</linkHtml>, <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, and <linkHtml href="#S7">Drug Interactions (7)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Hypersensitivity Reactions</content>
                        </paragraph>
                        <paragraph>Inform patients that anaphylaxis, serious skin reactions, and other hypersensitivity reactions have been reported, even following a single dose of PAXLOVID. Advise them to immediately discontinue the drug and to inform their healthcare provider at the first sign of a skin rash, hives or other skin reactions, difficulty in swallowing or breathing, any swelling suggesting angioedema (for example, swelling of the lips, tongue, face, tightness of the throat, hoarseness), or other symptoms of an allergic reaction <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Dosage Modification in Patients with Renal Impairment</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Moderate Renal Impairment</content>
                           </content>
                        </paragraph>
                        <paragraph>To ensure appropriate dosing in patients with moderate renal impairment, instruct such patients that they will be taking one 150 mg nirmatrelvir tablet with one 100 mg ritonavir tablet together twice daily for 5 days <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Severe Renal Impairment (Including Those Requiring Hemodialysis)</content>
                           </content>
                        </paragraph>
                        <paragraph>To ensure appropriate dosing in patients with severe renal impairment, including those requiring hemodialysis, instruct patients that they will be taking two 150 mg nirmatrelvir tablets with one 100 mg ritonavir tablet together <content styleCode="bold">once on Day 1</content>, followed by one 150 mg nirmatrelvir tablet with one 100 mg ritonavir together <content styleCode="bold">once daily on Days 2-5</content>. Instruct patients to take their dose at approximately the same time each day. On days when patients undergo hemodialysis, instruct them to take the PAXLOVID dose after hemodialysis <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Administration Instructions</content>
                        </paragraph>
                        <paragraph>Inform patients to take PAXLOVID with or without food at approximately the same time each day as instructed. Advise patients to swallow all tablets for PAXLOVID whole and not to chew, break, or crush the tablets. Alert the patient of the importance of completing the full 5-day treatment course and to continuing isolation in accordance with public health recommendations to maximize viral clearance and minimize transmission of SARS-CoV-2. If the patient misses a dose of PAXLOVID within 8 hours of the time it is usually taken, the patient should take it as soon as possible and resume the normal dosing schedule. If the patient misses a dose by more than 8 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. The patient should not double the dose to make up for a missed dose <content styleCode="italics">[see <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_cd7755d1-f4d3-4913-91c0-f80959da015f">
               <id root="6a03b528-2cda-4542-bf22-f75b80be719d"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>This products labeling may have been updated. For the most recent prescribing information, please visit <linkHtml href="http://www.pfizer.com">www.pfizer.com</linkHtml>. For Medical Information about PAXLOVID, please visit <linkHtml href="http://www.pfizermedinfo.com">www.pfizermedinfo.com</linkHtml> or call 1-800-438-1985.</paragraph>
                  <renderMultiMedia ID="id3967" referencedObject="bfc61552-958d-49a5-8e6c-c3e1b55a1ca1"/>
                  <paragraph>LAB-1523-5.0</paragraph>
               </text>
               <effectiveTime value="20250212"/>
               <component>
                  <observationMedia ID="bfc61552-958d-49a5-8e6c-c3e1b55a1ca1">
                     <text>Pfizer</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="PPI">
               <id root="2a0e9cdc-6d34-47cf-bb93-707a1b6713b0"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="35%"/>
                     <col width="15%"/>
                     <col width="1%"/>
                     <col width="3%"/>
                     <col width="16%"/>
                     <col width="29%"/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="6" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">PATIENT INFORMATION</content>
                                 <br/>
                                 <content styleCode="bold">PAXLOVID (pax-LO-vid)</content>
                                 <br/>
                                 <content styleCode="bold">(nirmatrelvir tablets; ritonavir tablets)</content>
                                 <br/>
                                 <content styleCode="bold">co-packaged for oral use</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about PAXLOVID? </content>
                              </paragraph>
                              <paragraph>PAXLOVID can interact with other medicines causing severe or life-threatening side effects or death. It is important to know the medicines that should not be taken with PAXLOVID. </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not take PAXLOVID if: </content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>you are taking any of the following medicines:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>alfuzosin</item>
                                 <item>
                                    <caption>o</caption>amiodarone</item>
                                 <item>
                                    <caption>o</caption>apalutamide</item>
                                 <item>
                                    <caption>o</caption>carbamazepine</item>
                                 <item>
                                    <caption>o</caption>colchicine</item>
                                 <item>
                                    <caption>o</caption>dihydroergotamine</item>
                                 <item>
                                    <caption>o</caption>dronedarone</item>
                                 <item>
                                    <caption>o</caption>eletriptan</item>
                                 <item>
                                    <caption>o</caption>enzalutamide</item>
                                 <item>
                                    <caption>o</caption>eplerenone</item>
                                 <item>
                                    <caption>o</caption>ergotamine</item>
                                 <item>
                                    <caption>o</caption>finerenone</item>
                                 <item>
                                    <caption>o</caption>flecainide</item>
                                 <item>
                                    <caption>o</caption>flibanserin</item>
                              </list>
                           </td>
                           <td colspan="4" valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>ivabradine </item>
                                 <item>
                                    <caption>o</caption>lomitapide</item>
                                 <item>
                                    <caption>o</caption>lovastatin</item>
                                 <item>
                                    <caption>o</caption>lumacaftor/ivacaftor</item>
                                 <item>
                                    <caption>o</caption>lurasidone</item>
                                 <item>
                                    <caption>o</caption>methylergonovine</item>
                                 <item>
                                    <caption>o</caption>midazolam (oral)</item>
                                 <item>
                                    <caption>o</caption>naloxegol</item>
                                 <item>
                                    <caption>o</caption>phenobarbital</item>
                                 <item>
                                    <caption>o</caption>phenytoin</item>
                                 <item>
                                    <caption>o</caption>pimozide</item>
                                 <item>
                                    <caption>o</caption>primidone</item>
                                 <item>
                                    <caption>o</caption>propafenone</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>quinidine </item>
                                 <item>
                                    <caption>o</caption>ranolazine</item>
                                 <item>
                                    <caption>o</caption>rifampin </item>
                                 <item>
                                    <caption>o</caption>rifapentine</item>
                                 <item>
                                    <caption>o</caption>St. Johns Wort (<content styleCode="italics">hypericum perforatum</content>)</item>
                                 <item>
                                    <caption>o</caption>sildenafil (Revatio<sup></sup>) for pulmonary arterial hypertension</item>
                                 <item>
                                    <caption>o</caption>silodosin</item>
                                 <item>
                                    <caption>o</caption>simvastatin</item>
                                 <item>
                                    <caption>o</caption>tolvaptan</item>
                                 <item>
                                    <caption>o</caption>triazolam</item>
                                 <item>
                                    <caption>o</caption>ubrogepant</item>
                                 <item>
                                    <caption>o</caption>voclosporin</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>These are not the only medicines that may cause serious or life-threatening side effects if taken with PAXLOVID. PAXLOVID may increase or decrease the levels of multiple other medicines. It is very important to tell your healthcare provider about all of the medicines you are taking because additional laboratory tests or changes in the dose of your other medicines may be necessary during treatment with PAXLOVID. Your healthcare provider may also tell you about specific symptoms to watch out for that may indicate that you need to stop or decrease the dose of some of your other medicines.</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>you are allergic to nirmatrelvir, ritonavir, or any of the ingredients in PAXLOVID. See the end of this leaflet for a complete list of ingredients in PAXLOVID. See <content styleCode="bold"><linkHtml href="#possiblesideeffects">What are the possible side effects of PAXLOVID?</linkHtml></content> for signs and symptoms of allergic reactions.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is PAXLOVID?</content>
                                 <br/>PAXLOVID is a prescription medicine used to treat mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. </paragraph>
                              <paragraph>PAXLOVID is not approved for use as pre-exposure or post-exposure treatment for prevention of COVID-19.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Before taking PAXLOVID, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>have kidney problems. You may need a different dose or dosing schedule of PAXLOVID.</item>
                                 <item>
                                    <caption></caption>have liver problems, including hepatitis. </item>
                                 <item>
                                    <caption></caption>have Human Immunodeficiency Virus 1 (HIV-1) infection. PAXLOVID may lead to some HIV-1 medicines not working as well in the future.</item>
                                 <item>
                                    <caption></caption>are pregnant or plan to become pregnant. It is not known if PAXLOVID can harm your unborn baby. Tell your healthcare provider right away if you are or if you become pregnant.</item>
                                 <item>
                                    <caption></caption>are breastfeeding or plan to breastfeed. PAXLOVID can pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with PAXLOVID.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>Your healthcare provider can tell you if it is safe to take PAXLOVID with other medicines.</item>
                                 <item>
                                    <caption></caption>You can ask your healthcare provider or pharmacist for a list of medicines that interact with PAXLOVID. </item>
                                 <item>
                                    <caption></caption>Do not start taking a new medicine without telling your healthcare provider. </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider if you are taking combined birth control (hormonal contraceptive).</content> PAXLOVID may affect how your hormonal contraceptives work. Females who are able to become pregnant should use another effective alternative form of contraception or an additional barrier method of contraception during treatment with PAXLOVID. Talk to your healthcare provider if you have any questions about contraceptive methods that might be right for you.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">How should I take PAXLOVID?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>Take PAXLOVID exactly as your healthcare provider tells you to take it. </item>
                                 <item>
                                    <caption></caption>
                                    <content styleCode="bold">PAXLOVID consists of 2 medicines: nirmatrelvir tablets and ritonavir tablets. The 2 medicines are taken together for 5 days. </content>
                                    <list listType="unordered">
                                       <item>
                                          <caption>o</caption>Nirmatrelvir is an oval, pink tablet.</item>
                                       <item>
                                          <caption>o</caption>Ritonavir is a white or off-white tablet.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <caption></caption>PAXLOVID is available in 3 Dose Packs (see <content styleCode="bold">Figures <linkHtml href="#PPI_FigureA">A</linkHtml>, <linkHtml href="#PPI_FigureB">B</linkHtml>, and <linkHtml href="#PPI_FigureC">C</linkHtml>
                                    </content> below). Your healthcare provider will prescribe the PAXLOVID Dose Pack that is right for you. Follow the instruction for the Dose Pack you receive.</item>
                                 <item>
                                    <caption></caption>
                                    <content styleCode="bold">If you have kidney disease, your healthcare provider may prescribe a lower dose (see </content>
                                    <content styleCode="bold">
                                       <linkHtml href="#PPI_FigureB">Figures B</linkHtml>
                                    </content>
                                    <content styleCode="bold"> and <linkHtml href="#PPI_FigureC">C</linkHtml>). Talk to your healthcare provider to make sure you receive the correct Dose Pack.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="6" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph ID="PPI_FigureA">
                                 <content styleCode="bold">Figure A</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="6" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">If you are prescribed PAXLOVID 300 mg; 100 mg Dose Pack<br/>Each dose contains 3 tablets taken together twice daily</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="6" styleCode="Rrule Lrule Botrule " valign="middle">
                              <renderMultiMedia ID="id338975075" referencedObject="cf2a0a0a-efce-485b-956a-957d4c1940fd"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="6" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">How to take PAXLOVID 300 mg; 100 mg Dose Pack</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="4" rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                              <renderMultiMedia ID="id1953592444" referencedObject="ID_71ae2f84-639f-4089-a4db-c3ddd5605b2c"/>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Morning Dose:</content>
                                 <br/>Take the 2 pink nirmatrelvir tablets and<br/>1 white to off-white ritonavir tablet together.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                              <renderMultiMedia ID="id141857755" referencedObject="bb9fc663-6831-401b-b2d0-51b16d8a80eb"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="4" rowspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <renderMultiMedia ID="id-78917003" referencedObject="BC69294D-F187-4B5A-B068-01F5161EAB1E"/>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Bedtime Dose:<br/>
                                 </content>Take the 2 pink nirmatrelvir tablets and<br/>1 white to off-white ritonavir tablet together.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                              <renderMultiMedia ID="id-1176801839" referencedObject="ID_59435584-b21a-4182-8ba0-c405465f6bb8"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="6" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph ID="PPI_FigureB">
                                 <content styleCode="bold">Figure B</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="6" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">If you are prescribed PAXLOVID 150 mg; 100 mg Dose Pack<br/>Each dose contains 2 tablets taken together twice daily</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="6" styleCode="Rrule Lrule Botrule " valign="middle">
                              <renderMultiMedia ID="id-1343163442" referencedObject="ID_96dd7e3d-39a5-4bc6-8812-32ff0c475b38"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="6" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">How to take PAXLOVID 150 mg; 100 mg Dose Pack</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="3" rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                              <renderMultiMedia ID="id663206312" referencedObject="ID_9d1ecc93-f819-483e-914a-b78966531564"/>
                           </td>
                           <td align="center" colspan="3" styleCode="Rrule Lrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Morning Dose:</content>
                                 <br/>Take the 1 pink nirmatrelvir tablet and <br/>1 white ritonavir tablet together.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="3" styleCode="Rrule Lrule Botrule " valign="middle">
                              <renderMultiMedia ID="id529459020" referencedObject="d8cc91f1-9dbd-48f8-875a-be6412571d55"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="3" rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                              <renderMultiMedia ID="id1000388257" referencedObject="ID_51a10c3b-f6f5-4965-bae1-1996c2239940"/>
                           </td>
                           <td align="center" colspan="3" styleCode="Rrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Bedtime Dose:<br/>
                                 </content>Take the 1 pink nirmatrelvir tablet and <br/>1 white ritonavir tablet together.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="3" styleCode="Rrule Lrule Botrule " valign="middle">
                              <renderMultiMedia ID="id652718573" referencedObject="ID_00965dfe-476c-460c-b3d0-bb3c6f3ab448"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="6" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph ID="PPI_FigureC">
                                 <content styleCode="bold">Figure C</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="6" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">If you are prescribed PAXLOVID 300 mg; 100 mg (Day 1) and 150 mg; 100 mg (Days 2-5) <br/>Each dose is taken together once daily; on days of dialysis take PAXLOVID after receiving dialysis</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="6" styleCode="Rrule Lrule Botrule " valign="middle">
                              <renderMultiMedia ID="id1743917715" referencedObject="ID_2ca34ec7-2ee4-470a-b490-75f11f62b5ea"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="6" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">How to take PAXLOVID 300 mg; 100 mg (Day 1) and 150 mg; 100 mg (Days 2-5)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2" rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                              <renderMultiMedia ID="id1613707194" referencedObject="ID_08dd218a-a256-4701-ba22-88c422569d74"/>
                           </td>
                           <td align="center" colspan="4" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Day 1 (First Day):</content>
                              </paragraph>
                              <paragraph>Take the 2 pink nirmatrelvir tablets and<br/>1 white ritonavir tablet together<br/>(<content styleCode="bold">Blue</content> part of the blister card).<br/>
                                 <br/>
                                 <renderMultiMedia ID="id1186792065" referencedObject="ID_6e3e3729-8dbe-4d06-834f-b4cacce970c6"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="4" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Days 2-5:</content>
                              </paragraph>
                              <paragraph>Take the 1 pink nirmatrelvir tablet and</paragraph>
                              <paragraph>1 white ritonavir tablet together</paragraph>
                              <paragraph>(<content styleCode="bold">Pink</content> part of the blister card).<br/>
                                 <br/>
                                 <renderMultiMedia ID="id1478577666" referencedObject="ID_9be37a5c-147a-4a4c-90d7-1a1a9457bfb6"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6" styleCode="Rrule Lrule Botrule " valign="middle">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>Do not remove your PAXLOVID tablets from the blister card before you are ready to take your dose.</item>
                                 <item>
                                    <caption></caption>If you are taking PAXLOVID tablets <content styleCode="bold">twice daily</content> (<linkHtml href="#PPI_FigureA">Figure A</linkHtml> or <linkHtml href="#PPI_FigureB">Figure B</linkHtml>), take your first dose of PAXLOVID in the morning or at bedtime, depending on when you pick up your prescription, or as your healthcare provider tells you to. <content styleCode="bold">Take your doses at around the same time each day.</content>
                                 </item>
                                 <item>
                                    <caption></caption>If you have severe kidney disease and are taking PAXLOVID tablets <content styleCode="bold">once daily</content> (<linkHtml href="#PPI_FigureC">FigureC</linkHtml>), follow the daily dose instruction on the blister card. <content styleCode="bold">Take your dose at around the same time each day</content>.</item>
                                 <item>
                                    <caption></caption>Swallow the tablets whole. Do not chew, break, or crush the tablets.</item>
                                 <item>
                                    <caption></caption>Take PAXLOVID with or without food. </item>
                                 <item>
                                    <caption></caption>Do not stop taking PAXLOVID without talking to your healthcare provider, even if you feel better.</item>
                                 <item>
                                    <caption></caption>If you miss a dose of PAXLOVID within 8 hours of the time it is usually taken, take it as soon as you remember. If you miss a dose by more than 8 hours, skip the missed dose and take the next dose at your regular time. Do not take 2 doses of PAXLOVID at the same time. </item>
                                 <item>
                                    <caption></caption>If you take too much PAXLOVID, call your healthcare provider or go to the nearest hospital emergency room right away.</item>
                                 <item>
                                    <caption></caption>If you are taking a ritonavir- or cobicistat-containing medicine to treat hepatitis C or HIV-1 infection, you should continue to take your medicine as prescribed by your healthcare provider.</item>
                              </list>
                              <paragraph>Talk to your healthcare provider if you do not feel better or if you feel worse after 5 days.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6" styleCode="Rrule Lrule " valign="top">
                              <paragraph ID="possiblesideeffects">
                                 <content styleCode="bold">What are the possible side effects of PAXLOVID?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">PAXLOVID may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>
                                    <content styleCode="bold">Allergic reactions, including severe allergic reactions (anaphylaxis) have</content> happened during treatment with PAXLOVID. Stop taking PAXLOVID and get medical help right away if you get any of the following symptoms of an allergic reaction:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>skin rash, hives, blisters or peeling skin</item>
                                 <item>
                                    <caption>o</caption>painful sores or ulcers in the mouth, nose, throat or genital area</item>
                                 <item>
                                    <caption>o</caption>swelling of the mouth, lips, tongue or face</item>
                              </list>
                           </td>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>trouble swallowing or breathing</item>
                                 <item>
                                    <caption>o</caption>throat tightness</item>
                                 <item>
                                    <caption>o</caption>hoarseness</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6" styleCode="Rrule Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>
                                    <content styleCode="bold">Liver problems</content>. Tell your healthcare provider right away if you get any of the following signs and symptoms of liver problems during treatment with PAXLOVID:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>loss of appetite</item>
                                 <item>
                                    <caption>o</caption>yellowing of your skin and the white of eyes</item>
                                 <item>
                                    <caption>o</caption>dark-colored urine</item>
                              </list>
                           </td>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>pale colored stools</item>
                                 <item>
                                    <caption>o</caption>itchy skin</item>
                                 <item>
                                    <caption>o</caption>stomach-area (abdominal) pain</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of PAXLOVID include:</content> altered sense of taste (such as metallic, bitter taste) and diarrhea.</paragraph>
                              <paragraph>Other possible side effects include:</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>headache</item>
                                 <item>
                                    <caption></caption>vomiting</item>
                                 <item>
                                    <caption></caption>abdominal pain</item>
                                 <item>
                                    <caption></caption>nausea</item>
                                 <item>
                                    <caption></caption>high blood pressure</item>
                                 <item>
                                    <caption></caption>feeling generally unwell</item>
                              </list>
                              <paragraph>These are not all of the possible side effects of PAXLOVID. For more information, ask your healthcare provider or pharmacist.</paragraph>
                              <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">How should I store PAXLOVID? </content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>Store PAXLOVID at room temperature between 68F to 77F (20C to 25C).</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep PAXLOVID and all medicines out of the reach of children.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of PAXLOVID.</content>
                                 <br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use PAXLOVID for a condition for which it was not prescribed. Do not give PAXLOVID to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for more information about PAXLOVID that is written for health professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in PAXLOVID?</content>
                                 <br/>
                                 <content styleCode="bold">Active ingredient:</content> nirmatrelvir and ritonavir<br/>
                                 <content styleCode="bold">Nirmatrelvir inactive ingredients:</content> colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, and sodium stearyl fumarate. Film-coating contains: hydroxy propyl methylcellulose, iron oxide red, polyethylene glycol, and titanium dioxide.<br/>
                                 <content styleCode="bold">Ritonavir inactive ingredients:</content> anhydrous dibasic calcium phosphate, colloidal silicon dioxide, copovidone, sodium stearyl fumarate, and sorbitan monolaurate. The film coating may contain: colloidal anhydrous silica, colloidal silicon dioxide, hydroxypropyl cellulose, hypromellose, polyethylene glycol, polysorbate 80, talc, and titanium dioxide.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <renderMultiMedia ID="id4105" referencedObject="ID_210a828d-131c-4688-91bc-712c155d1e30"/>
                              <br/>
                              <br/>
                              <paragraph>LAB-1524-4.0<br/>For more information, go to <linkHtml href="http://www.pfizer.com">www.pfizer.com</linkHtml> or call 1-800-438-1985.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration.Revised: 02/2025</paragraph>
               </text>
               <effectiveTime value="20250212"/>
               <component>
                  <observationMedia ID="cf2a0a0a-efce-485b-956a-957d4c1940fd">
                     <text>Figure A</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_71ae2f84-639f-4089-a4db-c3ddd5605b2c">
                     <text>Figure A1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="bb9fc663-6831-401b-b2d0-51b16d8a80eb">
                     <text>Figure A2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="BC69294D-F187-4B5A-B068-01F5161EAB1E">
                     <text>Figure A3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-07a.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_59435584-b21a-4182-8ba0-c405465f6bb8">
                     <text>Figure A4</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-07b.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_96dd7e3d-39a5-4bc6-8812-32ff0c475b38">
                     <text>Figure B</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_9d1ecc93-f819-483e-914a-b78966531564">
                     <text>Figure B1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="d8cc91f1-9dbd-48f8-875a-be6412571d55">
                     <text>Figure B2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-09a.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_51a10c3b-f6f5-4965-bae1-1996c2239940">
                     <text>Figure B3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-09b.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_00965dfe-476c-460c-b3d0-bb3c6f3ab448">
                     <text>Figure B4</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-09c.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_2ca34ec7-2ee4-470a-b490-75f11f62b5ea">
                     <text>Figure C</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_08dd218a-a256-4701-ba22-88c422569d74">
                     <text>Figure C1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-10a.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_6e3e3729-8dbe-4d06-834f-b4cacce970c6">
                     <text>Figure C2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-10b.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_9be37a5c-147a-4a4c-90d7-1a1a9457bfb6">
                     <text>Figure C3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-10c.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_210a828d-131c-4688-91bc-712c155d1e30">
                     <text>Logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_ae06693c-aa95-48a2-a31b-33ea2c05d2e7">
               <id root="8fe35ba0-0eb6-47aa-97ec-f543f452874d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 3 Tablet Blister Pack - 0069-5045</title>
               <text>
                  <paragraph>NDC 0069-5045-06</paragraph>
                  <paragraph>PAXLOVID<br/>(nirmatrelvir tablets;<br/>ritonavir tablets),<br/>co-packaged for oral use<br/>300 mg; 100 mg</paragraph>
                  <paragraph>nirmatrelvir<br/>tablet<br/>(150 mg)</paragraph>
                  <paragraph>Take these <br/>3 tablets<br/>together</paragraph>
                  <paragraph>ritonavir<br/>tablet<br/>(100 mg)</paragraph>
                  <paragraph>nirmatrelvir<br/>tablet<br/>(150 mg)</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>PAA203000<br/>Dist. by Pfizer Labs<br/>Div. of Pfizer Inc., NY, NY 10001</paragraph>
                  <paragraph>(01)10300695045063</paragraph>
                  <paragraph>LOT:<br/>XXXXXXX<br/>EXP:<br/>MM/YYYY</paragraph>
                  <renderMultiMedia ID="id4345" referencedObject="MM10"/>
               </text>
               <effectiveTime value="20231018"/>
               <component>
                  <observationMedia ID="MM10">
                     <text>PRINCIPAL DISPLAY PANEL - 3 Tablet Blister Pack - 0069-5045</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_5333afa4-b4df-48f4-8a2e-c19ff18c1341">
               <id root="cea7d995-f7c7-459f-b6b4-b3bf569e285e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - Kit Carton - 0069-5045 </title>
               <text>
                  <paragraph>Pfizer<br/>NDC 0069-5045-30</paragraph>
                  <paragraph>PAXLOVID<br/>(nirmatrelvir tablets; ritonavir tablets),<br/>co-packaged for oral use</paragraph>
                  <paragraph>300 mg; 100 mg Dose Pack</paragraph>
                  <paragraph>Take all 3 tablets from one blister<br/>card together, twice daily (in morning<br/>and at bedtime) for 5 days.</paragraph>
                  <paragraph>Each carton contains 30 tablets in 10 blister cards<br/>Each blister card contains 3 tablets:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption></caption>2 nirmatrelvir tablets (150 mg each)</item>
                     <item>
                        <caption></caption>1 ritonavir tablet (100 mg each)</item>
                  </list>
                  <paragraph>Note to pharmacist:<br/>Do not cover ALERT box with pharmacy label.</paragraph>
                  <paragraph>ALERT: Find out about medicines that<br/>should NOT be taken with Paxlovid</paragraph>
                  <paragraph>Rx only</paragraph>
                  <renderMultiMedia ID="id4375" referencedObject="MM11"/>
               </text>
               <effectiveTime value="20231018"/>
               <component>
                  <observationMedia ID="MM11">
                     <text>PRINCIPAL DISPLAY PANEL - Kit Carton - 0069-5045</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_5271b95a-09a0-4d8b-b1c4-75481df8fbab">
               <id root="ab0d96f0-7b4f-4eae-aee9-23dedfb7df3c"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 3 Tablet Blister Pack - 0069-5321 </title>
               <text>
                  <paragraph>NDC 0069-5321-03</paragraph>
                  <paragraph>PAXLOVID<br/>(nirmatrelvir tablets;<br/>ritonavir tablets),<br/>co-packaged for oral use<br/>300 mg; 100 mg</paragraph>
                  <paragraph>nirmatrelvir<br/>tablet<br/>(150 mg)</paragraph>
                  <paragraph>Take these <br/>3 tablets<br/>together</paragraph>
                  <paragraph>ritonavir<br/>tablet<br/>(100 mg)</paragraph>
                  <paragraph>nirmatrelvir<br/>tablet<br/>(150 mg)</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>PAA206981<br/>Dist. by Pfizer Labs<br/>Div. of Pfizer Inc., NY, NY 10001</paragraph>
                  <paragraph>(01)10300695321037</paragraph>
                  <paragraph>LOT:<br/>EXP:</paragraph>
                  <renderMultiMedia ID="id234591659" referencedObject="ID_610e41a2-ccd3-46b4-9d36-77364b773a85"/>
               </text>
               <effectiveTime value="20231018"/>
               <component>
                  <observationMedia ID="ID_610e41a2-ccd3-46b4-9d36-77364b773a85">
                     <text>PRINCIPAL DISPLAY PANEL - 3 Tablet Blister Pack - 0069-5321</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_775269e3-87e0-4f5f-ad8f-507ec26f73bd">
               <id root="6464949e-04cf-47e6-abe1-080e50261f5a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - Kit Carton - 0069-5321 </title>
               <text>
                  <paragraph>Pfizer<br/>NDC 0069-5321-30</paragraph>
                  <paragraph>PAXLOVID<br/>(nirmatrelvir tablets; ritonavir tablets),<br/>co-packaged for oral use</paragraph>
                  <paragraph>300 mg; 100 mg Dose Pack</paragraph>
                  <paragraph>Take all 3 tablets from one blister<br/>card together, twice daily (in morning<br/>and at bedtime) for 5 days.</paragraph>
                  <paragraph>Each carton contains 30 tablets in 10 blister cards<br/>Each blister card contains 3 tablets:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption></caption>2 nirmatrelvir tablets (150 mg each)</item>
                     <item>
                        <caption></caption>1 ritonavir tablet (100 mg each)</item>
                  </list>
                  <paragraph>Note to pharmacist:<br/>Do not cover ALERT box with pharmacy label.</paragraph>
                  <paragraph>ALERT: Find out about medicines that<br/>should NOT be taken with Paxlovid</paragraph>
                  <paragraph>Rx only</paragraph>
                  <renderMultiMedia ID="id550274951" referencedObject="D589C214-A5EE-4453-824D-F71E5D05BB73"/>
               </text>
               <effectiveTime value="20231018"/>
               <component>
                  <observationMedia ID="D589C214-A5EE-4453-824D-F71E5D05BB73">
                     <text>PRINCIPAL DISPLAY PANEL - Kit Carton - 0069-5321</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_34c7d9a5-1a81-458d-a8d7-6616f067668d">
               <id root="f34ee25b-e0e8-44ee-9ec1-bf3121b0e661"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 2 Tablet Blister Pack - 0069-5317 </title>
               <text>
                  <paragraph>NDC 0069-5317-02<br/>Rx only</paragraph>
                  <paragraph>nirmatrelvir<br/>tablet<br/>(150 mg)</paragraph>
                  <paragraph>This cavity<br/>intentionally<br/>left empty</paragraph>
                  <paragraph>Take these <br/>2 tablets<br/>together</paragraph>
                  <paragraph>PAXLOVID<br/>(nirmatrelvir tablets;<br/>ritonavir tablets),<br/>co-packaged for oral use<br/>150 mg; 100 mg</paragraph>
                  <paragraph>This cavity<br/>intentionally<br/>left empty</paragraph>
                  <paragraph>ritonavir<br/>tablet<br/>(100 mg)</paragraph>
                  <paragraph>Dist. by Pfizer Labs<br/>Div. of Pfizer Inc., NY, NY 10001</paragraph>
                  <paragraph>(01)10300695317023</paragraph>
                  <paragraph>LOT:<br/>EXP:<br/>PAA206982</paragraph>
                  <renderMultiMedia ID="id2054431065" referencedObject="ID_30d3ae47-de15-4fdc-a5a1-5f688d867819"/>
               </text>
               <effectiveTime value="20231018"/>
               <component>
                  <observationMedia ID="ID_30d3ae47-de15-4fdc-a5a1-5f688d867819">
                     <text>PRINCIPAL DISPLAY PANEL - 2 Tablet Blister Pack - 0069-5317</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-20.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_8b887982-165c-44f5-b7bc-35f9b94fe392">
               <id root="d0421040-9c91-4a83-8547-01cd8c9b47e6"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - Kit Carton - 0069-5317 </title>
               <text>
                  <paragraph>Pfizer<br/>NDC 0069-5317-20</paragraph>
                  <paragraph>PAXLOVID<br/>(nirmatrelvir tablets; ritonavir tablets),<br/>co-packaged for oral use</paragraph>
                  <paragraph>150 mg; 100 mg Dose Pack</paragraph>
                  <paragraph>Take both tablets from one blister<br/>card together, twice daily (in morning<br/>and at bedtime) for 5 days.</paragraph>
                  <paragraph>Each carton contains 20 tablets in 10 blister cards<br/>Each blister card contains 2 tablets:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption></caption>1 nirmatrelvir tablet (150 mg each)</item>
                     <item>
                        <caption></caption>1 ritonavir tablet (100 mg each)</item>
                  </list>
                  <paragraph>Note to pharmacist:<br/>Do not cover ALERT box with pharmacy label.</paragraph>
                  <paragraph>ALERT: Find out about medicines that<br/>should NOT be taken with Paxlovid</paragraph>
                  <paragraph>Rx only</paragraph>
                  <renderMultiMedia ID="id-1157919001" referencedObject="ID_9a5c4628-f417-4856-83ae-420c293f8798"/>
               </text>
               <effectiveTime value="20231018"/>
               <component>
                  <observationMedia ID="ID_9a5c4628-f417-4856-83ae-420c293f8798">
                     <text>PRINCIPAL DISPLAY PANEL - Kit Carton - 0069-5317</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-21.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_16f2e35d-e9a8-4b01-96f9-d219c2f70d3f">
               <id root="75acfa9d-9a47-46fd-82df-861670994ae6"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 11 Tablet Blister Pack - 0069-0521 </title>
               <text>
                  <paragraph>Day 1 (300 mg; 100 mg)<br/>Your first days dose. Take these 3 tablets together</paragraph>
                  <paragraph>nirmatrelvir<br/>tablet<br/>(150 mg)<br/>nirmatrelvir<br/>tablet<br/>(150 mg)<br/>ritonavir<br/>tablet<br/>(100 mg)</paragraph>
                  <paragraph>NDC 0069-0521-11<br/>Rx only<br/>PAXLOVID<br/>
                     <content styleCode="bold">(</content>nirmatrelvir tablets; ritonavir tablets), co-packaged for oral use</paragraph>
                  <paragraph>nirmatrelvir<br/>tablet<br/>(150 mg)<br/>Day 2 (150 mg; 100 mg)<br/>Take these<br/>2 tablets together<br/>ritonavir<br/>tablet<br/>(100 mg)</paragraph>
                  <paragraph>PAA228321</paragraph>
                  <paragraph>nirmatrelvir<br/>tablet<br/>(150 mg)<br/>Day 3 (150 mg; 100 mg)<br/>Take these<br/>2 tablets together<br/>ritonavir<br/>tablet<br/>(100 mg)</paragraph>
                  <paragraph>nirmatrelvir<br/>tablet<br/>(150 mg)<br/>Day 4 (150 mg; 100 mg)<br/>Take these<br/>2 tablets together<br/>ritonavir<br/>tablet<br/>(100 mg)</paragraph>
                  <paragraph>nirmatrelvir<br/>tablet<br/>(150 mg)<br/>Day 5 (150 mg; 100 mg)<br/>Take these<br/>2 tablets together<br/>ritonavir<br/>tablet<br/>(100 mg)</paragraph>
                  <paragraph>Dist. by Pfizer Labs, Div. of Pfizer Inc., NY, NY 10001</paragraph>
                  <renderMultiMedia ID="id215858922" referencedObject="ADDB7DA8-8792-4F28-9982-8ADE507B8701"/>
               </text>
               <effectiveTime value="20250131"/>
               <component>
                  <observationMedia ID="ADDB7DA8-8792-4F28-9982-8ADE507B8701">
                     <text>PRINCIPAL DISPLAY PANEL - 11 Tablet Blister Pack - 0069-0521</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-22.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a9c6979e-648a-4add-98b9-ab5587b21979">
               <id root="6d2b4a26-aa42-4774-94bb-aa2bbd165a4b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL  Kit Carton - 0069-0521 </title>
               <text>
                  <paragraph>Pfizer<br/>NDC 0069-0521-11</paragraph>
                  <paragraph>PAXLOVID<br/>(nirmatrelvir tablets; ritonavir tablets),<br/>co-packaged for oral use</paragraph>
                  <paragraph>300 mg; 100 mg (Day 1)<br/>150 mg; 100 mg (Days 2  5)</paragraph>
                  <paragraph>Day 1:<br/>Take 2 nirmatrelvir tablets and<br/>1 ritonavir tablet together<br/>Days 2 - 5:<br/>Take 1 nirmatrelvir tablet and<br/>1 ritonavir tablet together</paragraph>
                  <paragraph>Carton contains 1 blister card with 11 tablets:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption></caption>6 nirmatrelvir tablets (150 mg each)</item>
                     <item>
                        <caption></caption>5 ritonavir tablets (100 mg each)</item>
                  </list>
                  <paragraph>Note to pharmacist:<br/>Do not cover ALERT box with pharmacy label.</paragraph>
                  <paragraph>ALERT: Find out about medicines that<br/>should NOT be taken with Paxlovid</paragraph>
                  <paragraph>Rx only</paragraph>
                  <renderMultiMedia ID="id-1794278840" referencedObject="CEB8CA3B-E4AE-4E6A-ADF9-0E7B9C849689"/>
               </text>
               <effectiveTime value="20250131"/>
               <component>
                  <observationMedia ID="CEB8CA3B-E4AE-4E6A-ADF9-0E7B9C849689">
                     <text>PRINCIPAL DISPLAY PANEL  Kit Carton - 0069-0521</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="paxlovid-23.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>